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Malaria remains one of the greatest problems facing developing nations, especially in 
sub-Saharan Africa.  Part of the problem stems from increased resistance to current 
treatments hence there is a large drive to develop novel antimalarial compounds.  
Several chelating compounds, including 8-hydroxyquinoline (8-HQ), 1,10-
phenanthroline (1,10-phen) and 2,2:6,2-terpyridine (terpy), have disputed activities (8-
HQ and 1,10-phen) or are untested (terpy).  Furthermore the mechanism(s) by which 
these ligands and/or their complexes with metal ions exhibit their toxic effect is 
unknown.  In order to resolve these issues, a study of the antimalarial activities of the 
free ligands, the ligands complexed with metal ions (Au3+, Cu2+, Fe3+, Pd2+ and Pt2+), 
and the ligands with free metals in solution were measured.  The ligands, complexes and 
metals were also tested for their ability to inhibit β-haematin formation, the mode of 
action ascribed to the most widely used antimalarial, chloroquine.  The background 
toxicity levels of the various metal ions (previously unreported) were also measured and 
are reported here.  None of the ligands were found to have particularly high activity (all 
approximately 1 μM).  In general the metals in were found to have no beneficial effect 
on activity whether complexed or freely available in solution.  None of the ligands were 
found to inhibit β-haematin formation.  The complexes however, with the exception of 
those of Cu2+, all inhibited β-haematin formation.  Upon further investigation it was 
found that the each of the metal ions with the exception of Cu2+ had an innate ability to 
inhibit β-haematin formation.  Thus the mode of action of the ligands and the 
complexes is likely to be via different mechanisms.  In an attempt to enhance the 
activities of the ligands they were modified by covalently linking them to nutrients 
essential to the malaria parasite (adenosine and pantothenic acid).  These six novel 
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Introduction to Malaria 
1.1 The History of Malaria 
The human malaria parasite almost certainly developed at the same stage as early man, 
some two to ten million years ago, having evolved from the species that afflicted early 
apes approximately 30 million years ago.1  This new, human malaria, which at one stage 
was found almost everywhere on the globe is believed to have been spread by the 
migration of early Neolithic groups from central Africa to the Nile valley, 
Mesopotamia, India and South China.  The disease would later move from the Nile 
valley to Mediterranean Europe, as human settlements moved.  Of course the greatest 
aid to the proliferation of malaria has been the conquests of various nations during early 
history, from the Greeks to the Chinese, and in later history by those of the Spanish and 
Portuguese, who are most likely responsible for introducing malaria to the new world.1, 2 
 
Specific written records of the disease can often only be inferred from the symptoms 
described in ancient texts.  Mesopotamian tablets, dating back to 2000 BC and written 
in cuneiform, make mention of deadly periodical fevers which afflicted large parts of 
the population.1  Early civilizations in the Indus valley have left texts which also make 
reference to deadly fevers dating back to the Vedic (1500–800 BC) period, while 
Chinese scripts dating back as far as 2700 BC mention fevers with an associated 
enlargement of the spleen, symptoms typical of malarial infections.1  The ancient 
Greeks also made reference to what is undoubtedly malaria.  Hippocrates made the 
insightful connection between malaria and marshes, and noted that there were different 
types of malaria, distinguishable by the periodicity of their fevers.1 
 
As is typical of such early civilizations the cause of this affliction was often attributed to 
demons (Indian and Chinese), vengeful gods (Babylonian) or some other mythological 
reason, upset humours (Greek).1, 2  The association of malaria with marshes and swamps 
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would later lead to the name mal'aria from the Latin meaning "bad air".2  Ever since 
these ancient times, malaria developed a reputation for destroying armies, ending sieges 
and would continue to plague the armies of the world, during the 11th and 12th centuries.  
This would even occur as late as the 20th century, when the U.S. army became involved 
in Vietnam.1, 2  It has even been suggested that a nations plans for war can be seen by 
the medical research its army pursues.2  
 
Although man has been afflicted by this parasite for many years, centuries passed before 
humans would finally see the Plasmodium parasite and determine the role of the 
Anopheles vectora,3 in its life cycle.  In November 1880, the Frenchman, Charles-Louis-
Alphonse Laveran, became the first recorded person to see malaria parasites in the 
blood.  By analyzing a sample of blood from an infected soldier he saw not only 
gametocytesb,3 but also parasites in their ring stage form.  Soon he would identify four 
forms of the parasite: the male and female gametocytes, trophozoitec,3 and segmenterd 
stages of the parasite.4  Laveran would later report his findings to the French Academy 
of Medicine, but his claims were doubted, even scoffed at, and would continue to be 
treated thus for several years.  Only by 1895, with the aid of improved microscopes, and 
the work of Machiafava and Celli in Italy and Councilman and Abbott in the United 
States, would the life cycle of the parasite within the blood stages be fully understood.5  
 
By 1886, the organisms found by Laveran were generally accepted as being the cause of 
malaria, however the life cycle of the parasite was still unresolved.  Basil Danilewsky, a 
Russian zoologist-physician, had been studying the blood of birds between the years of 
1884 and 1889.2  In this blood he found remarkably similar parasites to those seen in 
human blood infected with malaria.  This finding sent many down the road of trying to 
link bird malaria to human malaria.  The reason for this was mostly because of an 
inability to see the parasites clearly since methylene blue, the most commonly used stain 
provided only a vague image of the parasite.  As is typical of science, a serendipitous 
                                                 
a A carrier of the malaria parasite. 
bThe sexual forms of the malaria parasite. 
cThe feeding stage form of the parasite. 
d The stages during which cell division takes place. 
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event would solve the problem.  In 1890-1891, while studying infected blood, Dr D. L. 
Romanowsky, a Russian army pathologist, left a bottle of methylene blue unstopperred, 
allowing it to grow mouldy.2  During this process he had in fact allowed the methylene 
blue to oxidize to a new compound, azure blue.  Despite the mould he continued to use 
his stain.2  This new stain gave never before seen detail of the parasites, and thus paved 
the way for better characterization of the various stages of the parasite's life cycle.  A 
year later, in 1892 with the aid of this new stain and more powerful microscopes, a team 
of Italian scientists, Amigo Bignami and Ettiore Marchiafava, proved that the various 
forms of malaria that had been seen, crescents, rings and gametocytes, were all stages of 
the life cycle of a single parasite.  This parasite was to be finally named Plasmodium 
falciparum (P.f.).2  Finally the blood stages of the parasite inside man were understood 
however the tissue stages were yet to be discovered while its transmission remained a 
mystery. 
 
Captain Ronald Ross an officer of the British Army and a newly qualified physician, 
would be the one to solve the problem of malaria's transmission.  Ross himself was a 
disbeliever of Laveran's work, and only became convinced when another Englishman, 
Patrick Manson, also a qualified physician showed him the parasites in the infected 
blood.2  It was Manson's belief that the mosquito was crucial to the spread of malaria, 
and as he became a mentor to Ross, Ross became bent on proving this connection.2  
After embarking to India, Ross fed mosquitoes on the blood of infected people 
containing sexual stage parasites for two years, expecting to see the development of 
spores within the mosquito.  Every time for two years the gametocytes would simply die 
in the mosquito's gut.  Over these two years, 1895-1897, Ross had the opportunity to 
view and dissect hundreds of mosquitoes, increasing not only his skills, but allowing 
him to become extremely familiar with the insects’ anatomy.  In 1897, by chance a 
servant would bring him ten mosquitoes of a type Ross had never seen before.  He fed 
these mosquitoes on infected blood, and began dissecting some each day for four days.  
On the fourth day Ross made his great discovery: on the exterior of the stomach wall of 
the mosquito was a cyst.  The following day he dissected his last mosquito, and found 
that not only were the cysts larger but they were alive and growing.  These mosquitoes 
are believed to have been Culex fatigans,2 a vector for bird malaria.  It must have been 
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pure coincidence that Ross had been delivered mosquitoes that had fed on infected 
birds.2  Although Ross's research would be interrupted by a new assignment from the 
British Army, his friend Manson managed to have him reassigned in order to allow him 
to continue his research.  A year later in 1898 Ross began to focus his work on avian 
malaria and by the end of June that year Ross had observed all stages of the malaria 
parasite in the mosquito.  The connection between the anopheline mosquito and human 
malaria transmittance would be made by the Italian Giovanni Battista Grassi, within a 
year of Ross's work.2  However due to scientific politics, Ross alone would collect the 
Nobel Prize in 1902.  The riddle of malaria's transmittance was solved.  The world 
could now embark on a mission to eradicate malaria forever. 
 
After the discovery that malaria was transmitted by mosquitoes there still remained the 
mystery as to the slow onset of infection in mosquito-bitten human.  In 1903 claims 
were made by Fritz Schaudin that he had seen sporozoitese,3 of Plasmodium vivax 
penetrating red blood cells.1  Due to his stature in the scientific community his claims 
would remain mostly unchallenged for the next 20 years.4  However during this time 
scientific evidence that the erythrocyticf,3 stages were not the only stages capable of 
multiple fission, was building.4  The same Grassi who was overlooked for the Nobel 
Prize had, in 1900, postulated that during the incubation period, a third developmental 
stage of the parasite should take place.  His beliefs were later to be given support by the 
findings of a Brazilian scientist, H. de Beaupaire Aragao, who after examining birds 
infected with Haemoproteus,g found forms of malaria, capable of dividing, that 
developed in the endothelialh,3 cells of the blood vessels in the lungs.6  de Beaupaire 
Aragoa would later show that the schizontsi,3 produced by these dividing forms were 
responsible for the invasion of erythrocytes and indirectly developed into gametocytes.4  
These findings were however, largely ignored.  By 1938 the identification of the exo-
erythrocyticj stages of the malaria parasite, in birds (only one stage is found in the 
human forms of malaria), was becoming more common.4  In 1944 Huff and Coulston 
                                                 
e Minute form of P.f. responsible for the invasion of cells (both red blood cells and liver cells). 
f The stages within the red blood cell (erythrocyte). 
g A parasite of the family Haemosporidia which infects the red blood cells of birds. 
h A thin layer of cells lining the blood vessel. 
i Cells that divide by schizogony (asexual reproduction by repeated division of the cell nucleus). 
j Stages which occur outside the red blood cell. 
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published the development from the sporozoites to the erythrocytic stages of 
Plasmodium gallinaceum.7  It was only as late as 1948 that Shortt, Garnham and their 
colleagues discovered the liver stage of parasites in rhesus monkeys infected with 
sporozoites of Plasmodium cynomolgi.  By taking liver tissue from human volunteers 
infected with Plasmodium vivax, they confirmed that a similar stage occurred in the 
human form of malaria.  Shortly there after they confirmed that the same was true for 
Plasmodium falciparum and described the full life cycle of the parasite.6 
 
With a better understanding of malaria (both the human stages and vector 
transmittance), governments around the world would embark on attempts to eradicate 
the parasite from their territories.  Various strategies and/or combinations thereof were 
adopted including: extensive prophylaxis (mostly using quinine); the use of various 
larvicides (e.g. petroleum oil and Paris green dust); the drainage of marshes and 
swamps; the introduction of cattle to farmland (cattle becoming the mosquito's food 
source); the introduction of natural mosquito predators (e.g. frogs, fish and even 
dragonflies); and the use of mosquito screens and bed nets.1, 2  In some countries these 
methods would prove extremely fruitful, as was the case in most European countries, 
while others would have only temporary or limited success.  A "natural" recession of 
malaria in northern Europe, as well as the USA, during the mid-19th century was 
probably the result of several factors, including the conversion of swamps and marshes 
into farmland, improved sanitation and greater access to medication.  The difference 
between success and failure has been related to, though not exclusively affected by, 
financial resources.  When financial backing has been adequate for third world 
countries, eradication attempts have been undermined by lack of infrastructure and 
organization, especially in countries, such as those in Africa, where rural populations 
dominate the landscape.  Methods that work well in more developed countries are often 
much harder to implement or sustain in the underdeveloped countries of Asia and 
Africa. 
 
In 1939, the discovery of the action of dichlorodiphenyltrichloroethylene (DDT), as an 
insecticide,8 would add a new weapon to the anti-malaria arsenal.  The compound, first 
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synthesized some 65 years earlier,9 was seen as a Godsend to end malaria.  There were 
several reasons for this belief: the cost of producing DDT was low; it had high toxicity 
to the insects with low toxicity towards man; it was toxic by contact; and the half life 
after spraying was extremely long.  Scientists later concluded that an application of one 
gram per square metre would continue to have an insecticidal effect for over 10 
months.10  However it was not to be.  Mosquitoes would soon develop resistance to 
DDT by evolving enzymes to detoxify the compound and by avoiding house walls after 
the blood meal.2  The physiological resistance to DDT, may have been a result of the 
excessive use of DDT by farmers, as opposed to its use against mosquitoes in 
eradication programmes.2  Although DDT did not lead to the world wide eradication of 
malaria it is still used as a vector controlling agent in various third world countries, this 
despite its being outlawed in several European countries and states in the US due to its 
toxicity and accumulation in the food chain. 
 
The understanding of the malaria life-cycle would also be a step forward to developing 
drugs to target the parasite selectively.  For many years malaria had been treated by 
qinghao (in China) and cinchona bark (in Europe).  While neither of these remedies was 
initially used as an antimalarial their effectiveness to treat fevers was identified in the 
16th and 18th centuries respectively, without any knowledge of the malaria life-cycle.    
In 1596 the qinghao herb was first recommended for the treatment of fever by Li 
Shizhen.  Only in 1972, through efforts by the Chinese government to investigate 
traditional remedies, was the active ingredient identified, qinghaosu (essence of 
qinghao).11  The bark of the cinchona tree was brought to Europe by Jesuit priests who 
had observed native Peruvians using it to stop shivering.  The bark was then tested on 
patients suffering from malaria and was found to treat the symptoms effectively.11  In 
1820 Pierre Pelletier and Joseph Caventou successfully isolated the active compound 
from the cinchona bark, quinine. 
 
Methylene blue, often used to stain parasites, became the first synthetic compound to be 
used to treat a disease, when in 1891, Paul Ehrlich, used the dye to cure two human 
patients of malaria.  This discovery led to Bayer, then mostly a dye company, becoming 
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one the biggest pharmaceutical companies worldwide.  Through its efforts Bayer 
developed plasmoquine, which prevented relapses of vivax malaria and mepacrine 
(atebrine) a compound effective against Plasmodium falciparum.  These two 
compounds became the most widely used during World War II after supplies of natural 
quinine became scarce when the Japanese captured Java (at one stage responsible for 
97% of the world’s supply).11  Due to the fighting in Africa as well as the Pacific, 
antimalarials formed an important part of the war effort, leading to collaboration 
between British, American and Australian scientists to develop better drugs.  In 1934, a 
compound called resochin was developed by H. Andersag, an employee for Bayer.  The 
compound showed high activity against malaria but was ultimately abandoned due to 
the perceived toxicity to humans.  Although the compound was shelved by the 
Germans, it was reinvestigated by the Allies during the war who ultimately found that it 
was suitable for use, and renamed it chloroquine.  Chloroquine became the most 
effective and widely used antimalarial ever.11  Several other antimalarial drugs also 
resulted from Allied research programs during the war.  The British developed 
proguanil, while American research brought the world primaquine (used to prevent 
relapses in Plasmodium vivax).  Other Allied discoveries became the precursors to some 
modern day drugs, including mefloquine, and atovaquone.  However at the beginning of 
the 1960s it became evident that chloroquine was losing its efficacy (probably due to its 
widespread use as a prophylactic) against falciparum malaria.  Today due to the 
increase in resistance of parasites to various antimalarials, drugs are often administered 
in combinations, in an attempt to ensure that the parasite is completely killed within the 
host, preventing the build-up of further resistance.11 
 
In 1998 the Roll Back Malaria (RBM) initiative was launched by the World Health 
Organization (WHO).  This initiative has renewed efforts to minimise the effects of 
malaria worldwide, their goals being to halve the burden by the year 2010 and to again 
halve the effect by 2015.12  As expected, the resistance of the malaria parasite to low 
cost drugs, together with the mosquito vector’s resistance to insecticides, has been a 
substantial setback.  This has brought more focus to preventing infection (such as the 
use of insecticide treated nets) and the use of combinations of drugs as opposed to 
single drug treatments, the two most prominent programs now endorsed by RBM.13 
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As of 2004 malaria was endemic in 107 countries with approximately 3.2 billion people 
exposed to infection (see Map 1.1.1 and Map 1.1.2).  It is estimated that between 300 
and 500 million clinical cases occur per year, caused primarily by Plasmodium 
falciparum and Plasmodium vivax.  Plasmodium falciparum is directly responsible for 
more than one million deaths (mostly African children under the age of five) annually, 
and may contribute to even more deaths in combination with other illnesses.  More than 
80% of these deaths take place in sub-Saharan Africa.   The mortality effect of malaria 
in Africa is amplified by the high rate of HIV/AIDS infections as well as the inability of 
public health systems to deal with such high infection rates.13  
 
 
Map 1.1.1 Areas currently at risk of malaria transmission (2003).14 
 
As with all diseases, prevention is better than cure, thus there has been a large drive by 
the WHO to distribute insecticide treated bed nets.  The nets provide a barrier which 
serves to stop the mosquito vector from transmitting the disease to people.  This has 




Map 1.1.2 Estimated clinical cases of malaria (any species 2004).14 
 
Unfortunately there are still of course many cases of infection, which must be treated 
with the drugs to which the parasite is growing evermore resistant.  It is now the 
recommendation of the WHO (since 2001) to supplement the most commonly used 
drugs, chloroquine and sulfadoxine-pyrimethamine, with some form of artemisinin 
derivative.  These approaches are referred to as Artemisinin-based combination 
therapies (ACTs) and are considered the most effective treatments in countries where 
resistance (to either drug) has been observed.15  However while many countries have 
“adopted” these strategies they are often not practised.  As of 2004 only nine of the 42 
countries which had adopted the strategy were actually practicing it.15  It is hoped that 
this combination approach therapy will help to maintain control of the pandemic while 
new drugs are developed. 
 
It is estimated by the report13 that an annual sum of US$ 3.2 billion would be required 
to control malaria in the 82 worst affected countries and while funding has recently 
increased it is still short of the desired target.  Most funding comes directly from 
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governments, which in Africa means finances are significantly short of that which is 
required for an effective antimalarial campaign.  Thus the RBM initiative is ever 




1.2 The Life Cycle of the Malaria Parasite: Plasmodium 
falciparum 
The malaria parasite undergoes a significantly intricate life cycle, requiring both human 
and mosquito hosts to proliferate.  Thus it is easier to look at the life cycle in these three 
parts: sexual development (taking place mostly in the mosquito-vector); exo-





In the case of P. f. a mere ten sporozoites is sufficient to cause an infection in the human 
host.  Within a period of 15-45 minutes all the sporozoites (Figure 1.2.1) will have 
invaded the relevant cells and disappeared from circulation.16  The sporozoites invade 
the parenchymala,3 cells of the liver (Figure 1.2.2) and then proceed to undergo 
schizogonyb,3 forming merozoites.c,17  In some cases hypnozoitesd,17 are formed as 
opposed to merozoites, and it is these hypnozoites which are believed to be responsible 
for relapses of malaria in patients.16  Hypnozoites do not occur in Plasmodium 
falciparum, but do in the remaining three forms of human malaria (P. vivax, P. ovale 
and P. malariae).  As in the case of the oocyst,e, 3 once the schizonts have matured the 
liver cell bursts releasing the merozoites into the bloodstream, where after they proceed 
to invade red blood cells. 
 
                                                 
a The functional cells of the liver (or any other organ). 
b Asexual reproduction by repeated division of the cell nucleus. 
c Cells formed by schizogony (asexual reproduction). 
d Dormant parasites which live in the liver. 
e A small cyst containing a fertilized egg (zygote, see sexual stages of reproduction). 
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Figure 1.2.1 Plasmodium falciparum sporozoites.18 
 
 




In the case of mammalian Plasmodium, merozoites are only capable of invading red 
blood cells (RBCs).  The merozoite is elongated in shape and goes through several steps 
to invade the RBC16: 
 
1) attachment to the RBC; 
2) reorientation of the apical end; 
3) apical junction formation; 
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4) formation of the vacuole; 
5) movement of the merozoite into the vacuole and 
6) sealing of the vacuole. 
 
It appears that the merozoite has the ability to attach itself at any point of contact 
between itself and the erythrocyte.  Once this has been achieved, the merozoite reorients 
itself so that the apical end is perpendicular to the RBC surface.  This allows the 
parasite to begin with active invasion of the cell.  Initially a junction is formed between 
the merozoite and the RBC, following which the merozoite empties the contents of its 
rhoptriesf,3 into the RBC membrane.  This begins the formation of the parasitophorous 
vacuole membrane (PVM).  The merozoite then proceeds to migrate into the RBC, 
while the PVM surrounds the parasite, and is finally sealed once the merozoite is 
completely within the RBC.16, 20 
 
At this stage the parasite looks like a minute circlet with a dot (the nucleus).  This is 
commonly known as the ring stage (Figure 1.2.3).  The parasite then begins to consume 
haemoglobin and grows into a mature trophozoite (Figure 1.2.4). 
 
 
Figure 1.2.3 Plasmodium falciparum early trophozoite (ring) stage.21 
 
                                                 
f Specialised secretory organelles belonging to the parasite. 
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During the consumption of haemoglobin a toxic by-product, haem, is produced.22  This 
by-product is crystallized out as haemozoing (a haem dimer)23 ensuring that it has no 
effect on the parasite. 
 
 
Figure 1.2.4 Plasmodium falciparum mature trophozoite stage.24 
 
Once it occupies approximately half the volume of the RBC, the parasite once more 
begins to undergo schizogony forming between eight and 24 merozoites (Figure 1.2.5) 
which are released into the bloodstream and restart the invasion cycle (Figure 1.2.6).2, 16 
 
 
Figure 1.2.5 Plasmodium falciparum fully matured schizont stage.25 
This cycle recurs approximately every 48 hours in cases of P. f. (but is different in other 
species) and as reported earlier is responsible for the periodic fevers experienced by 
malaria sufferers.  Occasionally the trophozoites will develop into gametocytes, instead 
of merozoites.  If this occurs, a mosquito vector can be infected upon taking a blood 
                                                 
g This precipitate is often seen in iRBCs as black spots and is referred to as malaria pigment.  
Synthetically it is known as β-haematin. 
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meal and the sexual stages of development are started.  A summary of the life cycle is 
shown in Figure 1.2.7. 
 
 
Figure 1.2.6 Plasmodium falciparum ruptured merozoites free from red blood cell.26 
 
 
Figure 1.2.7 Summary of the life cycle of the malaria parasite.h27 
                                                 
hReprinted from Trends in Parasitology Vol. 18, Kumar et al.,  A multilateral effort to develop DNA 





The parasite consumes haemoglobin while it occupies an host erythrocyte in order to 
gain access to many purine residues which it is incapable of synthesizing.22  As a result 
a toxic by-product, haem, is produced and thus the parasite must remove this toxicity.  
This toxin is removed when it forms a dimer which precipitates from solution, 
haemozoin (synthetically called β-haematin).23  The dimer is formed when the iron 
centre of one haem molecule coordinates to the propionate group on another.  This 
coordination is then reciprocated when the propionate group of the first haem molecule 
coordinates to the iron centre of the second.  These dimers are then hydrogen bonded to 
one another, as seen in Figure 1.2.8.  It is generally accepted that haem is capable of 
spontaneous dimerization under acidic conditions28 and the polymerization has recently 
been reported to be catalyzed by lipids.29  It is believed that chloroquine prevents the 
formation of this dimer by sterically blocking coordination,28 through interaction with 











































The sexual development of (P. f.) begins inside the human body, when, in the last stage 
of the life cycle, (a period of 48 hours usually culminating in the production of 
merozoites) gametocytes as opposed to merozoites are produced.  In P. f. asexual 
reproduction dominates the first ten days of infection following which, there is a surge 
of gametocytaemia.i,3  After this initial wave, gametocyte production becomes lower 
and less synchronized, (directly correlating with the periodicity of fevers in an infected 
person).32  These gametocytes have been shown to have a half-life of up to two days (in 
vitro) or two and a half days (in vivo) but may persist at levels allowing infection of the 
mosquito for up to 22 days.33  Infection of the mosquito vector occurs if gametocytes 
are taken up during a blood meal. 
 
Once in the mosquito’s stomach the gametocytes are released from the erythrocytes and 
converted into eight microgametes (from each male gametocyte Figure 1.2.9) and one 
macrogamete (from each female gametocyte Figure 1.2.10).16  To compensate for this 
imbalance it is typical for more macrogametocytes to be in circulation in the human 
host.  The microgametes are expelled with significant force during a process known as 
exflagellation (Figure 1.2.9). 
 
 
Figure 1.2.9 Plasmodium falciparum male microgametocyte exflagellation.34 
                                                 
i Production of sexual stages of the parasite. 
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Figure 1.2.10 Plasmodium falciparum female macrogametocyte.35 
 
The microgamete then fuses with a macrogamete to form a zygotej,3 (fertilization).16  
Within 18-24 hours the zygote becomes a mobile ookinetek,17 and breaches the stomach 
of the mosquito, whereupon it forms a cyst like body (oocyst) on the outer surface of the 
stomach wall.  Inside the oocyst, asexual reproduction takes place producing thousands 
of sporozoites (similar to schizonts).  Once the sporozoites have matured the oocyst 
bursts, releasing them into the haemocoele.l,3  Following this the sporozoites migrate to 
the salivary glands of the vector.16, 22  When the mosquito next takes a blood meal 
approximately 10% of the incumbent sporozoites are transferred to the human 
bloodstream and proceed to invade the liver cells. 
 
                                                 
j A fertilized egg. 
k A zygote of the parasite capable of spontaneous movement. 
l Spaces between the organs of the insect usually filled with a combination of blood, lymph and interstitial 
fluid. 
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1.3  Nutrient Transportation in the Infected Red Blood 
Cell 
General Transportation Properties 
 
The longest part of the malaria parasite’s life cycle is spent in the red blood cells 
(almost the full 48 hours of each life cycle in the case of P.f.), thus it is this stage which 
is the most suited for targeting by drugs.  However, because the parasite has invaded the 
host erythrocyte, an extremely complicated system of membrane transport is 
established.36-38  The nature of this membrane transport has been the source of intense 
study39-66 and debate47, 54, 67-72 (since the suggestion of a “parasitophorous duct”).67  
Pouvelle et al67 (and later others68, 70, 71) proposed the existence of a duct linking the 
parasite directly with the blood stream, in contrast to the more conventional idea of a 
sequential crossing of the three membranes (red blood cell membrane (RBCM), 
parasitophorous vacuole membrane (PVM) and parasite plasma membrane (PPM) see 
Figure 1.3.1).  Due to the parasites’ rate of replication it requires an immense quantity 
of nutrients (increasing approximately 24 fold in 48 hours).36-38  In order to ensure that 
sufficient food is obtained, the parasite exploits both endogenous RBC transport 
pathways and induces new permeation pathways (NPP).36-38  The fine details as to how 
the parasite gains access to exoerythrocytic nutrients may remain unresolved but it has 
been firmly established that infected red blood cells (iRBCs) accumulate more nutrients 
than normal RBCs.  Not only are nutrients accumulated/transported at a faster rate37, 44, 
45, 48, 61, 63 but there are also certain nutrients which are exclusively transported into 
iRBCs and essential to the survival of the parasite.37, 59, 61, 62, 66  These transport 
pathways are superb targets either by blocking them or using them as routes for drug 
delivery.43, 65, 73-76  Thus a literature investigation was performed to identify substrates 











Figure 1.3.1 Schematic showing membranes involved in trafficking of solutes in a malaria infected 
red blood cell.37* 
                                                 
* A demonstrates the traditional theory of sequential transport of solutes into the parasite.  B1 and B2 
represent two different applications of the theory of a “metabolic window” which is used for transport.  
C is representative of the “parasitophorous duct” as a mode of transportation of solutes into the parasite. 
 
Figure 1.3.1 shows the various modes of transport thought to take place in an iRBC.  
Diagram A demonstrates the traditional concept, of sequential transport across the three 
membranes, the RBCM, PVM and PPM, commonly referred to the “sequential 
pathway”.37  Diagram B represents two alternate pathways known as “metabolic 
windows”.  At B1 both the PVM and PPM are closely located to the RBCM to allow 
solute exchange directly between the parasite and the growth medium.77  Alternatively 
at B2 the tubovesicular membrane (TVM) is extended out from the PVM to the RBCM.  
Here it is postulated that the TVM is fused with the RBCM creating a specialized 
junction through which solutes may pass immediately to the parasite.  In both cases 
transport through the host erythrocyte is avoided.53  The so called “parasitophorous 
duct” is demonstrated in C.  Here a pathway exposing the parasite membrane to the 
external medium is created, and is believed to facilitate direct transport of 
macromolecules into the parasite.67  This idea of the duct is heavily debated47, 54, 68-72 
and although there is significant evidence for its existence,68, 70 there are alternative 
explanations for the observed experimental results.37  While its existence has not been 
disproven “the duct” is generally no longer supported by scientists in this field.  Figure 
1.3.1 highlights the complexity associated with drug delivery into the parasite.  There 
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may be even more membranes which need to be crossed, if for example a drug is only 
active in the food vacuole (FV).  It is likely that drugs which exhibit their effect by 
inhibiting the formation of β-haematina would need to locate there. 
 
In order to gain a better understanding of parasite transportation work has also been 
done to identify the genetic code that expresses transporters.55, 57, 61  Desai, Krogstad and 
McCleskey46 have even isolated the parasite from its erythrocytic host and used the 
patch clamp methodb,78 to investigate the nature of transportation on the PVM, 
demonstrating that transport across this membrane is largely unselective. 
 
Extensive work has been done in order to try to bring some understanding to the 
transport systems in use by the malaria parasite (including those of the iRBC).  This 
body of work has determined various factors affecting the rate of transport of solutes 
including, solute size,42, 48, 56, 63 charge48, 56 and even counterions.48, 49  While any or all 
of the above modes of transportation may be used by the parasite, the details of how the 
parasite takes up solutes is less important (to this study) than the actual solutes which 
are taken up, and how much.36-38  In order to ensure the delivery of these nutrients the 
parasite makes use of the endogenous RBC channels and transporters belonging to the 
red blood cell as well as NPPs39-43, 63 and accumulates and transports far more nutrients 
both in variety and quantity, when compared with healthy RBCs.
                                                 
a A synthetic form of haemazoin – the crystals formed by the parasite to precipitate the toxic haem by-
product which results from the consumption of haemoglobin. 






Introduction to Antimalarial Agents 
2.1 Transportation of Metal Ions into the Malaria 
Parasite 
 
The transportation and accumulation of metal ions into the malaria parasite is one aspect 
of the organism which is of particular interest to this study.  While there has been a 
significant amount of work performed on the transport and uptake of organic solutes, 
there has in contrast been very little research on the parasites preference for metals, 
especially for the transition metals copper, iron, gold and platinum. 
 
Due to the often trace amounts of gold and platinum in the human body it is not 
surprising that there is no report of the iRBCs ability to transport these metals.  With 
respect to copper and iron there is some, though little research, on the parasites need for 
these metals. 
 
It has been shown that during the parasites life cycle it has no need to accumulate 
copper, since the amounts present within the RBC prior to invasion are sufficient to 
support the parasite.79  It was even found that the parasite demonstrated pathways which 
in fact removed copper from the infected erythrocyte, leaving the infected parasite with 
approximately 66% of the amount found in a normal erythrocyte.79  Thus it appears that 
the parasite has an efficient copper efflux system to remove the toxic metal which is 
freed during the degradation of erythrocyte proteins.79 
 
In the case of iron there has been evidence to both suggest and refute the idea that iron 
is obtained from the serum, from the erythrocyte as free iron or from degraded 
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haemoglobin.  Reports in favour of transport from the serum are evidence for 
transferrina,17-independent iron transport80 and the resistance to malaria that people 
suffering from anaemiab,17 have shown.81  Arguments against the serum as a source of 
iron stem from the lack of transferrin receptors on iRBCs,82, 83 that iron supplemented 
diets had no effect on the course of malaria in infected patients84 and that there was a 
minimal increase in the uptake radiolabelled iron in iRBCs when compared with normal 
RBCs.85  The lack of activity from iron sequestration agents, when preloaded into 
erythrocytes, suggests that free erythrocytic iron is not required by the parasite68 and 
while haemoglobin degradation might seem an obvious source of iron,86 it has however 
been demonstrated by Egan et al.,87 that 95% of parasite digested haem iron can be 
found in haemazoin.  This however does not preclude the parasite from using the host 
erythrocyte as a source of iron, since the remaining iron (5%) might well be enough to 
supply the parasite.  The parasite’s source of iron is disputed but it has been 
demonstrated in the radiolabelled experiments of Scheibel et al.85 that free iron is 
inefficiently transported and accumulated by the malaria-infected erythrocyte.  They did 
however also prove that transport of this metal ion, and presumably others, such as 
copper, gold and platinum, can be mediated by ligands such as 8-hydroxyquinoline 
(uptake increased from 9% to 50% of serum iron in the presence of 8-
hydroxyquinoline).85 
 
What little research there is on the transport of metal ions (perhaps with exception of 
sodium and calcium) into the infected erythrocyte, suggests that in general 
transportation of metals into the parasite is likely to be mediated by organic ligands.  
This transport is exemplified by the case of 8-hydroxyquinoline and iron.  It is likely 
therefore that the ligands used in this study, 8-hydroxyquinoline, 1,10-phenanthroline 
and 2,2':6',2'' terpyridine might well facilitate the transport of metal ions (e.g. iron, 
copper, gold and platinum) into the iRBC. 
 
 
                                                 
a A protein responsible for the transport of iron into cells. 
b A condition in which a person has a low number of red blood cells, in this case caused by an iron 
deficiency. 
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2.2 The Use of 8-Hydroxyquinoline as an Antimalarial 
Agent and its Mode of Action 
 
The first investigation into the efficacy of 8-hydroxyquinoline (8-HQ) as antimalarial 
appears to have been carried out by Scheibel, Adler and Stanton in a series of papers 
from 1980 to 1986 (The Antimalarial Activity of Selected Aromatic Chelators).85, 88-90  
Their reason for investigating this compound was that it had similar characteristics to 
other compounds which had shown antimalarial activity.  These characteristics are the 
ability to inhibit metalloprotein oxidases and high binding constants for transition metal 
ions.  Both of these properties are possessed by 8-HQ.88  After the work by Scheibel et 
al., 8-HQ appears to have been largely ignored by the malaria scientific community, 
although it was recently reported to have extremely high activity (ten fold higher than 
chloroquine),91 while another paper reported only mild (μM) activity.92   The author of 
the former paper has produced no further reports on the activity of 8-HQ since his short 
communication. 
 
The initial study done by Scheibel and Adler88 revealed that this compound had an IC50 
of slightly less than 6.89 μM after one life cycle.  Later publications would report the 
activity found in this study to be as high as 8.3 nM,93 however this activity could only 
be attributed to 8-HQ after two parasite life cycles (96 hours), a practice not commonly 
used to measure the IC50 of antimalarials.  After the initial investigations the authors 
attempted to elucidate the possible mode of action of this compound. 
 
Their ideas for the mechanism by which 8-HQ kills the parasite came largely from work 
led by Adrien Albert in the late 1940s and early 1950s.94-97  This series of papers 
investigated the antibacterial activity of 8-HQ.  A range of 8-HQ related compounds 
(some of which can be seen in Figure 2.2.1) were first investigated to see which had 
higher activity.  The results of this study were: 
 
 25
1) only compounds with an hydroxyl substituent at the 8 position demonstrated 
activity (2-, 3-, 4-, 5-, 6-, and 7-hydroxyquinolines were all inactive); 
2) substitution at the 2 position reduced activity (as in the case of 2-methyl-8-
hydroxyquinoline, 2 ); 
3) hydrophilic groups reduced activity and 



























Figure 2.2.1 Selected compounds tested by Albert et al.94 
 
These results suggested that chelation was an absolute necessity for activity.94    
Furthermore the addition of various divalent metals (Ca2+, Mg2+, Mn2+, Fe2+, Cu2+ and 
Zn2+) to the growth medium were found to prevent the activity of 8-HQ.   Other 
chelators tested showed low activity, suggesting that a strong chelator would not 
necessarily demonstrate good antibacterial activity and that the molecular structure was 
important too.94  
 
In 1950 Albert, Gibson and Rubbo did more in depth studies into the bactericidal action 
of 8-HQ.95  In this study they at looked at how subtle changes in the growth medium 
affected the activity of 8-HQ.  This time the results were far more interesting: 
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1) the activity of 8-HQ was reduced or even halted when trace metals were 
removed from the growth medium; 
2) activity was restored upon the addition of cupric or ferric salts to a depleted 
growth medium (for Gram-positive organisms); 
3) cobalt was uniquely antagonistic to the action of 8-HQ; 
4) lowering the oxidation potential of the medium below -0.06 V stopped the action 
of 8-HQ; 
5) the presence of red blood cells (intact only) at 20% of the medium was found to 
lower the activity approximately 30 fold (something which might well hinder 
any potential antimalarial activity) and 
6) the action of 8-HQ was different in Gram-positive and Gram-negative bacteria, 
and differed from species to species within these two groups. 
 
The authors believed that these results point to the activity being due to an 8-HQ 
complex involving either copper or iron, which is responsible for the oxidation of a 
susceptible group associated with a metabolic process essential to the survival of the 
bacterium.  This is a direct conclusion of results 1 and 2 above.  It is also suggested that 
the protection afforded by cobalt is due to its ability to protect this group from 
oxidation.  This was concluded since nickel which has a higher affinity for 8-HQ 
afforded no such protection.  Both the nickel and cobalt 8-HQ complexes were shown to 
be non-toxic.95  Hence it would appear that the action of 8-HQ appears to be via some 
sort of Fenton mechanism.a,98 
 
Later the same team of authors investigated what the active complex might be.96  To do 
this they made a variety of growth media with different ratios of metal ions (Cu2+, Fe2+ 
and Fe3+) and 8-HQ.  The results of this study indicated the following: 
 
1) the action of 8-HQ was dependent on the presence of one or more of Cu2+, Fe2+ 
and Fe3+; 
                                                 
a The general group of reactions in which Fe3+ reacts with H2O2 to form an hydroxyl radical and an 
hydroxide ion. 
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2) when 8-HQ was present in large excess compared with the metal ions the 
activity dropped rapidly (activity was quickly restored upon the addition of at 
least half an equivalent of one of the metal ions) and 
3) when the metal concentration was increased beyond four equivalents was found 
to have an adverse effect on activity (though not as extreme as the effect caused 
by excess 8-HQ). 
 
These results have suggested that the nature of the 8-HQ-metal complex is important, 
i.e. whether a 1:1 complex, 5, or a 2:1 complex, 6, is present (see Figure 2.2.2).  The 
results above, in fact, suggest that a 1:1 complex is the cytotoxic species, since an 
excess of metal ions still results in some activity.  The authors’ final postulate is that the 
mechanism is a result of both the 1:1 and 2:1 complexes.  They describe a mechanism in 
which a lipophilic 2:1 complex is formed, facilitating transport across the cell 
membrane.  Once inside, an 8-HQ group dissociates, forming a 1:1 complex and freeing 
sites on the metal to allow the oxidation of sensitive groups (such as –SH) on enzymes 
or metabolites.96  The suggestion that a lipophilic complex is required for activity is 
supported by the behaviour of the complex formed with 4, which has identical affinities 








2:1 8-HQ:M lipophilic complex (M = Cu2+ or Fe2+)
6
1:1 8-HQ:M hydrophilic complex (M = Cu2+ or Fe2+)
5
 
Figure 2.2.2 Proposed complexes responsible for bactericidal activity of 8-HQ. 
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In order to further support the argument for the requirement of a lipophilic 2:1 complex, 
the authors synthesized a series of 8-HQ derivatives, both less and more lipophilic, and 
tested them for their bactericidal activity.  The more lipophilic compounds (determined 
using the oleyl alcohol:water partition coefficients) were found to have similar but not 
increased activity.  However the more hydrophilic compounds, 7, 8 and 9 , made by the 
addition of one or more nitrogen atoms into the aromatic rings of 8-HQ, were found to 
have markedly reduced activity.  Examples of some of the mono-, di-, and triazo 




















Figure 2.2.3 8-HQ species derivatised to increase hydrophilicity. 
The activity was found to decrease with an increase in the number of azo groups in the 
rings (7 > 8 > 9).97  Thus these results supported the authors hypothesis from 1953.96  
The results of these antibacterial studies would be the basis for the work done by 
Scheibel and co-workers when investigating the possible mode of action of 8-HQ on 
malaria parasites.85, 88-90 
 
In 1980 Scheibel and Adler reported their results for the antimalarial activity of 8-HQ 
(6.89 x 10-6 M) and two of its analogues, 2-methyl-8-hydroxyquinoline, 2, (6.28 x 10-4 
M) and 5-hydroxyquinoline (> 6.89 x 10-4 M).  These findings suggest that the activity 
of 8-HQ is derived from its chelating ability, since 2 showed reduced activity (possibly 
due to steric hindrance from the 2-methyl group), while 5-hydroxyquinoline (Figure 







Figure 2.2.4 Structure of 5-hydroxyquinoline. 
 
Following this, Scheibel and Adler investigated further derivatives (Figure 2.2.5) of 8-
HQ in 198189 and 1982.90  The aim behind this was to investigate the effect of 
lipophilicity on activity.  Furthermore the authors also investigated the effect of adding 
1 equivalent of cobalt, or 1 equivalent of copper/iron upon the activity of the 5-methyl 
species, 11, (see Figure 2.2.5).  Based on the findings of Albert, Rubbo and Gibson95, it 
was expected that cobalt would antagonize the activity of the 8-HQ derivatives while 
iron would potentiate it.  Upon testing it was found that neither transition metal had any 





























Figure 2.2.5 8-HQ derivatives tested by Scheibel and Adler.89, 90 
fact the only compound with comparable activity to 8-HQ itself was KAN-322 (IC50 = 
1.5 x 10-6 M).  The authors suggest that the lack of activity of benzo[f]quinolin-5-ol, 14, 
may be due to steric hindrance incurred when coordinating to the receptor site (which 
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may be different in the malaria parasite compared with those in the bacterial species 
studied by Albert et al.).94-97 
 
A series of results85 led the authors to later believe that the mechanism of action as an 
antimalarial was different from that found in the antibacterial studies:94-97 
 
1) the addition of copper or iron did not potentiate the effect of 8-HQ; 
2) no concentration quenching was observed at concentrations of 8-HQ which far 
exceeded those of iron or copper; 
3) increasing lipophilicity did not necessarily increase activity and 
4) neither cobalt nor EDTA antagonized the activity of 8-HQ. 
 
In light of this the authors decided to investigate whether in fact iron was carried into 
the parasite by 8-HQ.  This was done by adding 59FeCl3 to the growth medium.  The 
results showed that accumulation of 59Fe into the parasite was far greater and occurred 
at a much quicker rate in the presence of 8-HQ.  It was also found that approximately 
30% of the iron taken into the red blood cell (55% of the total in the growth medium) 
was located in the parasites. Surprisingly KAN-322 was also found to transport 59Fe 
into the red blood cell (35% of the total in the growth medium) of which an impressive 
65% was located in the parasite itself.85  The increased accumulation of the 59Fe-(KAN-
322) complex inside the parasite may be due to pH trapping made possible by the 
secondary and tertiary amines located on the side chain of KAN-322.  Following the 
results the authors suggest that saturating the metals (iron or copper) with 8-HQ prior to 
addition to the growth medium may provide a better understanding of the mechanism.  
Presumably this would help to determine exactly which complex is responsible for the 
antimalarial activity of 8-HQ (i.e. a 1:1, 2:1 or 3:1 complex).  However there appear to 
be no further reports from these authors on the mode of action of 8-HQ. 
 
The next report in the literature of 8-HQ with respect to its antimalarial activity is by 
Egan, Ross and Adams, in a paper in which the authors investigate the ability of 
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compounds to inhibit spontaneous β-haematinb formation in situ.28  The main aim of 
this paper was to demonstrate a quick assay to determine this action.  It was suggested 
by Egan et al. that chloroquine acts by directly preventing the formation of haemozoin 
crystals (naturally occurring β-haematin), which normally removes toxic haemin (a by-
product from the digestion of haemoglobin) from solution.28, 30  In this paper28 8-HQ is 
not attributed any antimalarial activity (although it is not tested in this report) and does 
not prevent the formation of β-haematin.  Hence it seems likely that this is not the mode 
of action of the compound.  Other authors have proposed that chloroquine acts on an 
enzyme responsible for the formation of haemozoin31, 99 and has even been suggested to 
inhibit DNA replication100.   
 
In 2004 Roberts et al.92 tested the ability of 8-HQ to inhibit the proliferation of malaria 
parasites.  The objective of their paper was to demonstrate the presence of a previously 
unidentified alternative oxidase common to apicomplexan parasitesc,17 (the investigation 
included Toxoplasma gondii and Plasmodium falciparum but concentrated on 
Cryptosporidium parvum).  The authors demonstrated that both salicylhydroxamic acid 
(SHAM) and 8-HQ inhibited the growth of P.f. (and in fact all three parasites) at similar 
concentrations.  The authors suggested that the inhibition of this alternative oxidase may 
be the mode of action of these compounds. 
 
In 2003 Biswas91 reported an investigation into the activity of 8-HQ.  In this paper an 
IC50 of between 1 and 10 nM against both chloroquine-susceptible and chloroquine 
resistant strains of the parasite was reported.  The IC50s for chloroquine in this report are 
between 0.41 μM (chloroquine susceptible strains) and 3.45 μM (chloroquine-resistant 
strains), activity much lower than 8-HQ.  These results appear to be in contradiction 
with almost all previously published data on the antimalarial activity of 8-HQ as well 
that reported by Roberts et al.92 (activity of 11 μM and 8.6 μM against a chloroquine 
resistant and chloroquine susceptible strain respectively).  To date no further details on 
this high activity have been reported by Biswas. 
                                                 
b The synthetic form of haemozoin.  Chloroquine is believed to act by inhibiting the formation of this 
crystal. 
c Parasites which have an organelle known as the apical complex, believed to be used during cell 
invasion. 
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Clearly there has been some confusion over the antimalarial activity of 8-HQ,28, 88, 91, 93 
and while the mode of action against bacteria seems well studied,94-97 there remains 
some question as to how the compound acts against the malaria parasite.  The first aim 
of this study is to determine, independently, the activity of 8-HQ against P.f., and to 
either confirm or refute one or more of the previously reported activities.88, 91  Second, 
the role of metal ions in the activity of this ligand is also to be investigated, i.e. are ions 
such as Fe3+ or Cu2+ essential for 8-HQ to exhibit its toxic effect (as they are for 8-HQ’s 
antibacterial activity), and if so what is in fact the active species?  Third, some 
investigations will be done to gain insight as to the possible mode of action of this 
compound (it should be noted however, that mechanistic studies are extremely 
complicated due to the nature of the parasite).  Thus it is the overall aim of this study to 




2.3 The Use of 1,10-Phenanthroline as an Antimalarial 
Agent and its Mode of Action 
 
The compound 1,10-phenathroline (1,10-phen, Figure 2.3.1) has been shown to cleave 
DNA in a Fenton-type mechanism similar to that believed to be the antibacterial mode 
of action of 8-HQ.101  When the ability of 1,10-phen to inhibit Escherichia coli DNA 
Polymerase I (Pol I)a,98 was first discovered, it was attributed to this ligands affinity for 
Zn2+ and the sequestration of this ion from the polymerase.  This was demonstrated by 
dialysis of the holoenzymeb,3 against 1,10-phen, and subsequent lack of activity 
thereafter.102  However Sigman and coworkers would later show, over several years, 
that this mode of action was unlikely, and that a (1,10-phen)2Cu+ complex was 
responsible for a Fenton-mediated destruction of DNA, the products of which facilitate 





Figure 2.3.1 The structure of 1,10-phenanthroline. 
 
After confirming the inhibitory effect of 1,10-phen on Pol I, D’Aurora et al.103, 
demonstrated that this activity was dependent on a 2:1 ratio of 1,10-phen:Cu2+/+ and a 
thiol (it would later be shown that dihydronicotinamide, NADH, could also facilitate the 
single electron reduction of Cu2+ to Cu+, although at a much slower rate)109 is used to 
facilitate the reduction of Cu2+ to Cu+.  In this paper it was further demonstrated that 
                                                 
a One of several enzymes which catalyzes the formation of DNA. 
b A combination of the protein component of an enzyme (apoenzyme) and the functioning part of an 
enzyme (coenzyme). 
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other metals (Co2+/3+, Zn2+, Fe2+/3+ or Cd2+) did not have the ability to facilitate cleavage 
of poly (dA-T), used in place of Pol I to measure DNA cleavage ability.  Following this 
the same authors showed by a series of experiments that the 2:1 complex must be the 
active form of the ligand.104  This was done by demonstrating that 9-phenanthroic acid 
(a non-chelator with the same skeletal structure) did not demonstrate any inhibitory 
ability when used in place of 1,10-phen.  However 2,9-dimethyl-1,10-phenanthroline, a 
chelator specific for Cu+, totally prevented inhibition at a ten fold excess, implying the 
necessity of Cu+ ions for activity.  The lack of activity of 2,9-dimethyl-1,10-
phenanthroline suggested that steric hindrance might prevent it from approaching the 




Figure 2.3.2 The structure of 2,9-dimethyl-1,10-phenanthroline. 
 
A year later in 1979 Sigman et al.105 demonstrated two important aspects of the activity 
of the (1,10-phen)2Cu+ complex.  The first was an absolute necessity for O2 (far lower 
activity was observed under anaerobic conditions) and secondly that it is in fact the 
products of the DNA cleavage by (1,10-phen)2Cu+ which are responsible for the 
inhibition of Pol I.  To prove the latter point, the authors cleaved poly(dA-dT) under 
normal conditions,105 quenched the reaction by adding of 2,9-dimethyl-1,10-
phenanthroline (20 fold the concentration of 1,10-phen) and took an aliquot of the 
quenched reaction to add to a matrix containing Pol I.  This solution containing Pol I 
and the aliquot had much lower activity when compared with a control matrix 
containing no aliquot.  The rate of the inhibition reaction was also shown to be fast 
(occurring within one minute of the addition of reagents) further indicating that the 
products of cleavage are responsible for activity and not sequestration of zinc from the 
polymerase, as previously suggested.102  
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Graham et al.106 would go on to show that superoxide is generated during the reaction of 
the complex with DNA, but that superoxide itself is not responsible for cleavage, since 
other superoxide generators had no cleaving effect.  The same group later discovered 
that hydrogen peroxide could be used in place of molecular oxygen, that the complex 
showed no preference for any of the four nucleic bases (A, T, C or G) and that there is 
an almost absolute preference for double stranded DNA.107  Pope and Sigman would 
later show that the complex would preferably cleave B-DNA (only 10-20% of A-DNA 
is cleaved while no cleavage of Z-DNA is observed).110  This result implies that there is 
a preference for cleavage of DNA over RNA since RNA occurs only in the A form. 
 
Thedarahn et al.108 would go on to postulate the mechanistic scheme for the reaction of 
(1,10-phen)2Cu+ with DNA.  Their conclusions were essentially a direct result of the 
identification of the cleavage products,110, 111 the work done by Sigman and his 
coworkers described above104-107 and that of other scientists112.  The simplistic 
mechanism involves the formation of the (1,10-phen)2Cu2+ complex, which is then 
reduced in a single electron transfer reaction to (1,10-phen)2Cu+.  This species is then 
reversibly bound to DNA and oxidized by hydrogen peroxide to generate the copper-
oxo species responsible for the DNA cleavage products.  This non-covalent bonding is 
believed to occur non-intercalatively, in the minor groove of the DNA.  In line with this 
postulation derivitization at the 5 position was found to have no steric effect on DNA 
scission, suggesting that this position could be exploited to target scission more 
specifically.  The mechanistic scheme can be seen in Figure 2.3.3. 
 
(1,10-phen)Cu2+ (1,10-phen)Cu+





Figure 2.3.3 Mechanistic scheme for DNA scission by 1,10-phenanthroline-copper complex. 
The most common use of 1,10-phen with regards to malaria appears to be in classifying 
proteases as metalloproteases.113-115  However more recently the compound has been 
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incorporated into inorganic complexes and tested116, as a protease inhibitor during 
various stages of parasite development117, 118 and has been derivatized and tested against 
malaria.119-121  At the conception of this project it was apparent that 1,10-phen itself had 
not been tested for its antimalarial activity (although some derivatives were tested as 
early as 2000).119  Since then however at least three articles have been published on the 
antimalarial activity of this compound and its derivatives.116-118 
 
The use of 1,10-phen in a preformed inorganic complex, 18, as an antimalarial by Egan 
et al.116 appears to be the earliest use of this ligand.  The ligand was used to form 










Figure 2.3.4 An example of a 1,10-phenanthroline complex tested as an antimalarial.116 
 
These complexes were designed to facilitate π−π stacking, and expected to act by 
preventing β-haematin formation.  Most of the compounds were found to have a strong 
ability to inhibit β-haematin formation, but no correlation between β-haematin 
inhibition and activity was found, possibly due to the cationic nature of the 
compounds.116   In fact the compounds with the weakest β-haematin inhibition had the 
highest in vitro antimalarial activity (IC50 of 0.141 μM).  All of the ligands themselves 
were shown to have no ability to inhibit β-haematin formation, however their 
antimalarial activities, as free ligands, were not investigated. 
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In 2005 Torres et al.117 investigated the effect of protease inhibitors during 
gametogenesis and the early zygote stages of parasite development.  Amongst the 
inhibitors used was 1,10-phen.  The ligand was found to totally inhibit gametogenesis at 
concentrations > 500 μM (whereas the IC50 is approximately 200 μM).  This effect was 
shown to be markedly reduced (a mere 4.93% inhibition using a concentration of 600 
μM) with the addition of Zn2+, an effect often observed due to the ligand’s affinity for 
this cation. Once this had been determined the ability to prevent various stages of 
parasite development from gametogenesis to ookinete development was investigated.  
This was done by introducing the inhibitor to gametocyte-infected blood cultures 
(ranging from t = 0 to t = 120 min).  The inhibitory effect of 1,10-phen (1 mM) was 
found to reduce almost linearly with time, and had almost no effect at 120 minutes, 
suggesting that it is only active during gametogenesis (t = 0 min) and the early zygote 
stages.  However this only applies to the vector-based stages of the life cycle and has no 
relevance to the stages inside the human host. 
 
A year later (2006), Kitjaroentham et al. appear to have been the first group to test 1,10-
phen against malaria in vitro.118  In their work the authors have made a strong case to 
suggest that the action of this ligand is via its ability to inhibit the invasion of red blood 
cells by the parasite.  The authors identify three steps which are involved in their 
invasion inhibition assay: schizont development; merozoite release from the red blood 
cell; and merozoite invasion of a new red blood cell.  To rule out a mode of action 
which acts during the first step, parasites were isolated at the schizont stage of 
development and exposed to 1,10-phen.  In a second experiment parasitophorous 
vacuolar membrane-enclosed structures (PEMS) containing merozoites (merozoites 
contained in a vacuole free of the red blood cell) were treated with 1,10-phenantholine.  
The IC50s were found to be similar (25 μM and 29 μM), suggesting that neither schizont 
development nor escape from the red blood cell was inhibited.  To further demonstrate 
that merozoite release is not affected, 1,10-phen was compared with E64, a compound 
previously shown to inhibit release.122  When parasite proliferation is inhibited and the 
mode of action is prevention of merozoite release, a far greater number of schizont 
infected red blood cells are observed, which was the case for E64, but not for 1,10-phen.  
This article does well to suggest that the mode of action of 1,10-phen may be via 
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inhibition of invasion, but there is no evidence in this paper to suggest that 1,10-phen 
does not inhibit other metalloproteases or even act by an entirely different mechanism, 
during the earlier stages of parasite development.  An alternative mode of action would 
be suggested if a lower IC50 was found when testing 1,10-phen over a longer period of 
the parasites life cycle. 
 
Prior to the work described above there has been an investigation into the activity of 
some 1,10-phen derivatives.119  The investigations included the 1,10-phen derivatives 
shown in Figure 2.3.5.  Of these the methyl-quarternized species, 20, was found to be 
the most active, 0.19 μM, a ten fold increase on the activity of the parent molecule, 2.4 
μM.  The fact that this compound exhibited the highest activity suggests implicitly that 
the mode of action is not due to metalloproteases inhibition, since steric hindrance 
prevents the quarternized 1,10-phen species from coordinating a metal ion.  Recently 
Yapi et al.120 reported again that quarternization of the nitrogen at the 10 position 
enhanced the antimalarial activity of a 1,10-phen derivative (also ten fold of that of the 
parent molecule 3.29 μM to 0.35 μM).  This article also reported in vivo antimalarial 
results, but only looked at the most active in vitro compound (20), no comparison was 






















21 22  
Figure 2.3.5 1,10-phenanthroline derivatives previously tested for antimalarial activity.119, 120 
 39
Wijayanti et al.121 have gone on to test a series of quarternized 1,10-phen compounds in 
vivo (mouse model, Plasmodium berghei).  The compounds, 23 - 28, are shown in 
Figure 2.3.6.  The N-benzyl derivatives were found to be more active than the N-alkyl 
derivatives, reportedly due to the more lipophilic nature of the N-benzyl derivatives.  
The activity of the salts was found to be I > Cl > Br (active in the same order of 
magnitude, however) while 28 was found to have reduced activity, which the authors 
propose may be due to the extra bulkiness introduced by the para-methoxy group.  
Compared with chloroquine however these compounds have a ten fold lower activity 
and a much lower therapeutic index (toxicity towards malaria divided by toxicity 
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Figure 2.3.6 1,10-Phenanthroline derivatives tested in vivo against Plasmodium berghei infected 
mice.121 
 
This concludes the extent to which the antimalarial effect and mode of action of 1,10-
phen has been investigated to date.  While 1,10-phen has been well established as a 
DNA intercalator,101 its antimalarial effect has been ascribed to different modes of 
action, including β-haematin formation inhibition (as a complex),116 inhibition of 
metalloproteases (as a free ligand)118 and an unknown mechanism (for quarternized 
1,10-phenanthrolines).119  It is quite possible that each of these types of compounds 
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(complexes, the free ligand or quarternized ligands) act via a different mechanism.  
With respect to 1,10-phen therefore it is intended to, as far as is possible, investigate 
whether the ligand’s activity is different when used alone or when combined with free 




2.4 The Use of 2,2':6',2'' Terpyridine and its Mode of 
Action 
 
Around the same time that Sigman and his group were working on the action of 1,10-
phen, another researcher, S.J. Lippard began his extensive study into the ability of 
2,2':6',2'' terpyridine (terpy, Figure 2.4.1) complexes to bind to DNA.  Lippard 
demonstrated that platinum (II) terpy complexes, especially those ligated with a thiol 
compound, were capable of intercalating DNA.123  It has been demonstrated that several 
other complexes of terpy (Au3+ or Cu2+)124, 125 are also capable of intercalating into 
DNA and that the binding constant can be adjusted by changing the accompanying 
ligand.123, 126, 127  Only recently have some terpy complexes been tested for their 
antimalarial activities in a patent released by Lowe.128  However neither the free ligand 
nor its complexes with several transition metals, Au, Cu or Fe, has been tested for 
antimalarial activity.  In light of paucity of literature on the antimalarial activity of terpy 
compounds, a brief review of terpy anticancer studies has been done.  This should give 
some insight on the potential modes of action and types of terpy compounds which have 






Figure 2.4.1 Structure of 2,2':6',2'' terpyridine. 
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The Modes of Action of 2,2':6',2'' Terpyridine and its Complexes 
 
In 1974 Jennette et al.123 demonstrated through several techniques, that platinum (II) 
complexes of terpy, the chloride, 30, and 2-hydroxyethanethiol species, 31, in particular 
(Figure 2.4.2), intercalated into DNA.  The results of various forms of analysis 
suggested that intercalation was taking place, and that it was of a similar nature to that 
observed for ethidium bromide.123  However it was apparent that the binding observed 
for 30 was weaker than 31, attributed (by the authors) to the lability of the chloride 
ligand.123, 126  Using X-ray fiber diffraction patterns  Bond et al.129 demonstrated that the 
interaction with calf thymus DNA (CT-DNA) is intercalative and further that it is via 
the neighbour exclusion binding model (where platinum is found in every other 
interbase pair site).  Reports have also shown that complexes with a net +2 charge have 
stronger intercalative binding constants,127 e.g. 4-picoline-Pt-terpy complex 32 (Figure 
2.4.2).  This complex was found to have an intercalative binding constant two orders of 


























Figure 2.4.2 Terpyridine species shown to intercalate DNA by Jennette et al.123 and 4-picoline-
terpy-Pt(II).127 
 
While the DNA intercalating ability of Pt-terpy species has been known for many years, 
it has also been shown that 32, in particular, is capable of platinating the nitrogen atoms 
on some nucleosides, in a way similar to that of cisplatin.130  Using NMR studies Lowe 
and Vilaivan showed that the nucleosides adenosine and guanosine (and their 2'-deoxy 
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derivatives) were capable of displacing the 4-picoline ligand, resulting in platination of 
one or more nitrogen atoms on the nucleosides (N7 for the two guanosine species and 
both N1 and N6 in the two adenosine species).  This is the mode of action of cisplatin 
and is a possible alternative mode of action for Pt-terpy complexes in general. 
 
In 2001 Messori et al.125 reported an investigation into the binding of several gold(III) 
complexes with DNA among which were those seen in Figure 2.4.3.  All of the binding 
was weak and reversible, and the authors suggest that it was mostly electrostatic in 
nature.  From their evidence the authors concluded that Au-terpy initially binds 
intercalatively and slowly switches to a coordinative mode of binding.125  The nature of 
the interaction of these compounds with DNA is implied as the mode of action for their 
















Figure 2.4.3 Gold(III) complexes investigated for their and DNA binding affinity125 anti-tumor 
activity.131 
 
Recent results have suggested that the different terpy complexes (e.g. the Au3+ and Pt2+ 
complexes) have different rates of intercalation.132  In these studies the authors found 
that [Au(terpy)Cl]Cl2 only showed evidence of retardation after three hours while 
[Pt(terpy)Cl]Cl demonstrated retardation of DNA within one hour (electrophoresis with 
CT-DNA used in all cases).  The authors here believe that the action of the Au3+ 
complex is due to an initial electrostatic interaction which through slow kinetics 
converts to a coordinative interaction. 132 
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In 2006 a series of phenyl-terpy gold derivatives were tested for DNA binding 
capabilities and anticancer activities.133  Both the free ligands and the gold complexes 
were tested.  While the gold complexes, 35-37 (Figure 2.4.4), were shown to bind DNA 
no evidence was found to suggest that the free ligands were capable of any binding.  
The authors also demonstrated that intracellular DNA was bound to the complexes by 
measuring the gold content in extracted DNA using Inductively Coupled Plasma Mass 






















Figure 2.4.4 Gold(III) complexes of and ligands (without Au centre) investigated for both DNA 
binding affinity and antitumor activity.133 
 
The interaction of some Cu-terpy derivatives with DNA has also recently been 
studied.124, 134  These derivatives were found to bind intercalatively to DNA but had 
only moderate binding constants (104 M-1).  It was also demonstrated that the complexes 
were capable of DNA scission in the presence of hydrogen peroxide (similar to the case 
of Cu-phen species in the presence of hydrogen peroxide as demonstrated by 
Sigman).101  These appear to be the only studies on the behaviour of Cu-terpy 
complexes with DNA.  In light of the ability of terpy complexes to intercalate and 
platinate DNA they would appear to be good candidates for anticancer therapy (or even 
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for the treatment of malaria), since they should help to localise drugs within the DNA of 
tumour (or parasitic) cells. 
 
The Biological Activity of 2,2':6',2'' Terpyridine and its Complexes 
 
The earliest investigation into the biological activity of terpy was reported in 1985 by 
McFayden et al..135  The authors investigated the in vitro and in vivo (mouse model) 
anticancer activity of a series of 1,10-phen and terpy platinum(II) intercalating 
complexes, among others.  The highest activities were for the two 1,10-phen complexes 
39 and 40 seen in Figure 2.4.5 (IC50s of 0.7 μM and 2 μM, in vitro).  For the terpyridine 
series complexes with thiolato counter ligands had the highest activity, e.g. the terpy 
complex 41.  [Pt(terpy)Cl]Cl had the lowest activity of terpy series, IC50 of 450 μM.  
The terpy ligand, when tested uncomplexed to a metal, had activity higher than any of 
its associated complexes  It has been suggested that the activity of the free ligands could 
be attributed to a metal sequestration mechanism, or the formation of toxic metal 
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Figure 2.4.5 Complexes active against Leukemia L1210.135 
 
Following these results, the most in depth study of the activity of terpy complexes has 
been by a group under Lowe128, 136-140  Their initial work was an investigation into the 
cytotoxicity of terpy-platinum complexes against the protozoa Leishmania donovani, 
 46
Trypanosoma cruzi and Trypanosoma brucei.136  Most of the complexes tested had a 
pyridine-type counter ligand (see Figure 2.4.6), as these have higher DNA intercalation 
binding constants (~ 106 – 107 M-1).136  However complexes with more labile ligands, 
Pt(terpy)Cl+, Pt(terpy)H2O2+ and Pt(terpy)NH32+, did in some cases exhibit higher 
antiparasitic activity than complexes designed with pyridine-type counter ligands.  The 
authors also investigated the effect of derivatising the four position on terpy.  From 
these results they discovered that a chloro or para-bromophenyl group enhanced 
activity the most.  Complexes with these derivatives and an ammonia counter ligand, 47 
and 48, gave the highest (47) antiparasitic activity.  While these two complexes gave 
significant activity in all three species of protozoan, the activity of each complex was 
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Figure 2.4.6 Pt(terpy) complexes tested against the protozoa L. donovani, T. cruzi and T.  brucei.136 
 
The mechanism of action here could be due to either DNA intercalation or DNA 
platination.136  Attempts to discern which mechanism might be occurring, by using a 
terpy platinum complex with a thiol ligand did not provide any clarity as to the mode of 
action of these compounds.  Shortly after this, Lowe et al.138 published anticancer 
results for a similar series of terpy complexes, most of which were the same as those 
used in the earlier study. 136  The activity against several human ovarian cancer cell lines 
was tested.  The activities of the free ligands were not reported in either study. 
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Bonse et al.137 (2000) have reported that the most active platinum-terpy complexes (i.e. 
47 and 48) of their earlier work136 are capable of inhibiting T. cruzi trypanothionea,17 
reductase.  This inhibition was irreversible, strongly suggesting that this is the target of 
platinum-terpy complexes, and suggests that enzyme inhibition is a further possible 
mode of action for these compounds.  Interestingly Pt-terpy complexes have been 
shown to bind, reversibly, to a cysteine residue on recombinant human serum albumin.b, 
17, 139  Ross et al.139 suggest that this ability might be the transport mechanism which 
platinum-terpy complexes use to localise into cancerous cells.  Furthermore it implies 
that the mode of action of these drugs could be via the irreversible binding to cysteine 
residues found on other important enzymes.139 
 
In 2001, Becker et al.,140 demonstrated exactly this.  The authors showed that the 
platinum-terpy complexes were capable of inhibiting human thioredoxin reductase 
(hTrxR) irreversibly under in vivo conditions.  This enzyme is responsible for DNA 
synthesis (transcription), autocrine growth stimulation and antioxidant defence, and is 
upregulated in tumour cells.  Due to the affinity of platinum for thiol groups, it is likely 
that the selenocysteine residue is the site of attack by the complexes.140  This work has 
been buoyed by the recent in vivo studies by Becker et al.141  who demonstrated that the 
same mechanism occurs in rat models, treated with platinum-terpy complexes.  They 
found that in rats treated with the complexes 49 and 50 (Figure 2.4.7), TrxR activity was 
reduced in several organ tissues (e.g. kidney, liver and skin) as well as in tumour cells.  
The compounds were found to be effective against established tumours and had higher 
anticancer activity than that observed for cisplatin. 
 
                                                 
a An enzyme which reduces thioredoxins (proteins which act as antioxidants). 

















Figure 2.4.7 Complexes tested in rat models for TrxR inhibition.141 
 
Around the same time that Lowe and his group were researching the activity of Pt-terpy 
complexes another group, under Messori were looking at Au-terpy complexes.  In 2000 
they reported the antitumor activity of a series of gold(III) complexes (Figure 2.4.3).131  
While the report on the antitumor activity of these complexes shows that the terpy (IC50 
0.1 – 0.3 μM) and 1,10-phen (IC50 2.7 – 3.7 μM) complexes are the most active.  It is 
interesting to note that the ligands themselves (terpy and 1,10-phen alone) were as toxic 
as their corresponding complexes.  This activity is loosely ascribed to the formation of 
toxic metal complexes (e.g. Cu-phen) or metal sequestration.131 
 
The antitumor activity of the complexes in Figure 2.4.4 was reported in 2006.133  The 
most active species was 36, 80% inhibition at 10 nM, approximately 105 greater activity 
than cisplatin.  Interestingly each of the corresponding ligands has slightly better 
activity than its associated gold complex.  In the cases of the complexes the DNA 
binding affinity was found to correspond to the activity.133  No explanation is given for 
the higher activity observed for the ligands themselves.  While it is perhaps unintended 
the authors have demonstrated that, as seen before, terpy-type ligands often have as 
good as or better activity than the metal complexes thereof, which brings into question 
the necessity of transition metals for activity.  
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In 2006 the anticancer activity of the terpy ligand itself was tested.142 Zhao et al.142 
prepared several terpy compounds (Figure 2.4.8), being various combinations of 2, 3 
and 4 substituted pyridines.  None of the compounds, with the exception of 2,2':6',2'' 
terpyridine showed any reasonable activity (the other terpyridine compounds were 1 
000 fold less effective than 2,2':6',2'' terpyridine).  The activity of terpy was better than 
or as good as the activity of current anticancer drugs (doxorubicin and camptothecin) in 
almost all the cell lines investigated.  It also reported that terpy has no topoisomerase Ic,3 
inhibitory activity, implying that this is not the mode of action of this compound.  This 
paper however has demonstrated, as seen before,133 that ligands themselves are capable 
of high anticancer activity, although the mechanism by which ligands and complexes 
























Figure 2.4.8 Terpyridine compounds screened  against several human cancer cell lines, all lacking 
activity.142 
 
The Use of 2,2':6',2'' Terpyridine as an Antimalarial Agent 
 
As stated earlier the only reported use of terpy (or complexes thereof as antimalarials) 
has come from Lowe in a patent.128  The three compounds investigated, 56, 57 and 58 
                                                 
c An enzyme responsible for cutting and rejoining a single DNA strand, altering the topology of the DNA. 
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(see Figure 2.4.9), had IC50s of 2.7 μM, 20.6 μM and 2.4 μM respectively.  No 
















Figure 2.4.9 Terpyridine species tested by Lowe128 (all as BF4 salts, and the only terpy species to 
have been tested for antimalarial activity to date). 
 
Unlike 8-HQ and 1,10-phen, very little investigation into the antimalarial activity of 
terpy has been done.  For this reason it is the aim here to determine whether terpy and 
its complexes, which have demonstrated good anticancer activity, have similarly good 
antimalarial action (as one patent has reported).128  And while the behaviour of terpy 
complexes with DNA is well documented, there is no guarantee that its interaction with 
DNA is responsible for any activity which might be observed in antimalarial studies.  
Hence a study of the antimalarial action of both terpy alone, as well as the complexes of 
terpy with several metal ions, including Pt2+, Au3+, Cu2+ and Fe3+ will be undertaken.  
As in the case with both 8-HQ and 1,10-phen, there are many possible mechanisms by 
which the ligand and its complexes might exhibit activity (e.g. metalloprotease 
inhibition, β-haematin formation inhibition, DNA intercalation or platination or metal 
sequestration).  Therefore efforts will also be made to gain insight into the mode of 
action of the free ligand and its complexes to determine whether they are in fact the 




The literature which covers the antimalarial activity of the three ligands, 8-HQ, 1,10-
phen and terpy, is slightly different in each case.  However the questions surrounding 
the activities and mode of action of each of the ligands are very similar.  An extensive 
study including all three ligands in the same study has also not yet been performed.  
Each of the ligands has been demonstrated to have a significant amount of activity in an 
alternative area of biochemistry: 8-HQ as an antibacterial; 1,10-phen as a DNA scission 
agent; and terpy as an anticancer agent.  In each of these applications it has been shown, 
or sometimes assumed, that the activity is dependent on the presence of metal ions, 
whether in a premade complex or by complexation in situ.  It is necessary therefore to 
investigate what the role of metal ions in the action of these compounds is.  In order to 
do this several experiments must be performed: 
1) the toxicity of free metal ions must be investigated as these have to date never 
been reported; 
2) the toxicities of the free ligands should be investigated to provide a base activity; 
3) the effect of free metals at high, but non-toxic levels in the growth medium, on 
the activities of the free ligands should be investigated; 
4) the toxicities of premade ligand-metal complexes should be investigated and 
5) the ability of each compound to inhibit haemazoin formation should be 
investigated. 
 
These five points describe the work which should bring clarity and add to the current 
literature.  Point 1 will provide insight as to the toxicity of various metal ions to the 
parasite.  Point 2 will bring clarity to the disputed activity of 8-HQ and 1,10-phen and 
will also be the first report in open literature of the antimalarial activity of terpy.  Points 
3 and 4 will help to determine the importance and role of metals in the mode of action 
of these compounds, whether they act by formation of a toxic complex, metalloenzyme 
inhibition or metal sequestration.  Point 5 will be useful in determining whether 
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haemozoin formation inhibition might be the mode of action of the metals, ligands or 
their complexes. 
 
Thus it is the aim of the work here to provide a solid foundation on the antimalarial 
activities of the metals (Cu2+, Fe3+, Au3+ and Pt2+) and ligands (8-HQ, 1,10-phen and 
terpy).  The secondary aim is to investigate role(s) that these metal ions play in each of 





3.1 Nutrients Selective to Plasmodium falciparum 
Infected Red Blood Cells 
The Exploitation of Parasite Transport Systems 
 
There has been a substantial amount of work covering the transport into and 
accumulation of solutes in the malaria-infected RBC.  Important to our study however is 
the iRBCs requirement for two solutes, pantothenic acid (which is exclusively 
transported by the iRBC)59, 62, 64, 66 and L-adenosine (which is accumulated to a much 
higher extent in the iRBC than the normal RBC).50 
 
In the treatment of any illness, drug delivery is extremely important.  From Figure 1.5.1 
(Chapter 1) it is apparent that in malaria it is even more complicated than usual because 
the parasite “hides” in the human erythrocyte.  A drug must therefore cross at least three 
membranes to reach the parasite (and even more to reach organelles or specifically the 
food vacuole).  Thus it may be possible, by selecting solutes which are exclusively or 
preferentially, transported or accumulated by iRBCs to enhance the activity and/or 
selectivity index of a drug when attached to a carrier molecule.38, 43, 53, 74  Four different 
ways of exploiting the parasite and iRBCs NPP have been described38.  The most 
obvious is to use compounds to block the nutrient transport pathways, essentially killing 
the parasite through starvation.143-145  The second strategy which has been employed 
involves a combination approach.  By using a toxic compound together with a 
compound which inhibits a normal RBC channel, the toxic compound is selectively 
accumulated by the iRBC.65, 74  This selectivity is due to the parasites use of both 
endogenous transport pathways and the NPP (see Figure 3.1.1).  A third approach is to 
develop compounds that are only activated when metabolised and ensure that they are 
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selectively metabolised by the parasite.  The final approach is to exploit the parasites 
requirement for a particular nutrient by using the NPP to deliver a toxic compound with 
the nutrient,43, 53, 65 sometimes referred to as a Trojan horse or magic bullet strategy.38  
These methods have been exploited by Gero et al.65 who developed an L-nucleoside 
derivative which was selectively metabolised by the parasite, but was otherwise 
inactive.  In this report Gero et al.65 made use of both of these final two strategies and 




Figure 3.1.1 Nucleoside transport in a normal (top) and infected (bottom) RBC when using a dual 




Pantothenic acid (Figure 3.1.2) has been identified as one the few solutes which is 
absolutely essential to the survival of the parasite P.f..59, 146  Saliba et al.62 showed that 
                                                 
a Figure appears in Current Pharmaceutical Design Vol. 9 Iss. 11 pp. 867-877 (2003).  Reprinted from 
Parasitology Today Vol. 8, Gero and Upston,,  Altered Membrane-Permeability - a New Approach to 
Malaria Chemotherapy, pp. 283-286, Copyright (1992), with permission from Elsevier. 
 55
this transport is via the NPP expressed by the iRBC, and that the normal RBC expresses 














Pantothenic Acid 59 Adenosine 60  
Figure 3.1.2 Targeting agents for Plasmodium falciparum. 
 
phosphorylation within the parasite (rate of phosphorylation P.f./RBC = 10), and not in 
the host erythrocyte implying that transport of this solute is indeed across all three 
membranes (RBCM, PVM and PPM).62  It is likely that transport across the PVM is 
easily achieved due to its unselective nature (previously described by Desai, Krogstad 
and McCleskey46) and Saliba and Kirk64 have demonstrated that transport across the 
PPM is mediated by H+.  The transport of pantothenate across this membrane was found 
to be dependent on H+ concentration and independent of Na+ concentration (in contrast 
with mammalian cells).  The authors also discovered that the parasite’s pantothenate 
kinase has a much higher affinity for pantothenate than the mammalian kinases.  The 
kinase is efficient at phosphorylating and thereby trapping this substrate, at high 
concentrations, inside the parasite cytosol.64  Previously it had been demonstrated that 
the P.f. trophozoites could accumulate pantothenate to up to 150% of the external 
concentration within 20 minutes.  Following these findings Saliba and Kirk have moved 
in the direction of identifying analogues of pantothenate which exhibit antimalarial 







A second nutrient for which the parasite has an exclusive affinity (when compared with 
normal erythrocytes) is L-adenosine (Figure 3.1.2).50  This is most probably as a result 
of the parasite’s high requirement for nucleosides, as it is incapable of de novo purine 
synthesis.22  The endogenous erythrocyte nucleoside transporter is selective for the D-
isomer of this compound and does not show any appreciable transport of the L-isomer.50  
This finding was the result of several studies in which Gero and coworkers44, 45, 50 first 
demonstrated that the uptake and incorporation into polynucleotides of adenosine by 
iRBCs was almost unaffected by nitrobenzylthioinosine (NBMPR), a known inhibitor 
of the erythrocyte nucleoside transporter.44  The conclusion from this result was that the 
parasite must be making use of the NPP, which ones specifically remained unknown, 
either new nucleoside trafficking routes had been developed, or the RBC transporter had 
been sufficiently modified to render it insensitive to the inhibitor.44  Thus it became 
apparent that it may be viable to treat malaria using two drugs: an erythrocyte 
nucleoside transport inhibitor, and a toxic nucleoside.44  It was in fact shortly thereafter 
demonstrated that this hypothesis held true (at least in vitro), and that NBMPR (IC50 4.2 
μM) and the toxic nucleoside tubercidin (IC50 0.51 μM) were shown to have a 
synergistic effect used together [activity was at concentrations lower than would be 
ascribed to a purely additive effect, determined by Fractional Inhibitory Concentration 
(FIC) values].45  Upston and Gero50 discovered that the iRBC was in fact transporting 
L-adenosine as well as the D-isomer.  In this study50 they established that the transport 
which was occurring was active (i.e. not simple diffusion), non-saturable and that the L-
adenosine was metabolised into L-inosine and not incorporated (1/10th of the amount of 
D-adenosine) into nucleic acid material.  Several L-adenosine transport inhibitors were 
also identified.50  In 1998 Penny et al.61 injected Xenopus laevis oocytesb,3 with mRNA 
isolated from P.f. parasites.  From this technique it was demonstrated that P.f. encodes 
its own transporters of nucleosides, nucleobases, hexoses and monocarboxylates.  The 
uptake of D-adenosine by this transporter was stereospecific (not inhibited by high 
concentrations of the L-isomer), purine selective and insensitive to inhibitors of 
                                                 
b An immature egg cell of the species Xenopus laevis commonly used in studies involving the expression 
of RNA and/or DNA  
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erythrocyte transporters.61  Brown et al150 would go on to show that the parasite 
adenosine deaminasec (ADA) is upregulated 1000 fold, compared with that in the 
uninfected erythrocyte.  In addition the parasite ADA alone was capable of 
metabolizing L-adenosine into L-inosine, an additional difference between the treatment 
of the L-nucleoside in iRBCs and normal RBCs.150  Mammalian ADAs in general do 
not use the L-isomer.151 
 
In 2000 two groups independently55, 57 reported the identification of a P.f. nucleoside 
transporter, designated PfNT155 and PfENT157 respectively.  The two proteins were 
identical with the exception of one base position.57  A detailed analysis of the transport 
properties of this protein was made by Carter et al..55  Their findings were that PfNT1 
had a high selectivity for adenosine over other nucleosides and that the transporter was 
selective for D-adenosine, but not stereoselective for it (both the D- and L-isomers were 
transported, although the rate of uptake of the D-isomer was much higher).55  The 
inability for known NPP inhibitors48 to affect the D-adenosine55 uptake suggests that 
this transport pathway is not involved in NPP transport discovered by Kirk.48  This 
transporter was later located at the PPM, using immunogold labelling techniques.58  
Both sets of authors indicate that the parasite’s ability to transport L-isomers of 
nucleosides is an excellent means by which to deliver toxic compounds.55, 57  An 
excellent exploitation of this transport pathway was demonstrated by Gero et al.65, when 
they chemically bonded 2'-deoxy-L-adenosine (a carrier) with 5-fluoro-D-2' 
deoxyuridine-monophosphate (a cytotoxic nucleoside) via a phosphate linker.  The 
compound was designed to make use of both selective transportation and the parasite 
ADA’s ability to metabolize the L isomers of adenosine.  The advantage of these drugs 
really lies in the lack of toxicity towards mammalian cells, (non-toxic to mice treated 
with doses as high as 400 mg/kg).65  A key part to the strategy of Gero et al.65, is that 
the compounds are non-toxic until metabolised. 
 
                                                 
c An enzyme responsible for the irreversible conversion of adenosine to inosine (converting an amine 
group to a ketone, deamination) 
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In this project it is hoped that compounds such as pantothenic acid and adenosine will 
confer increased transport and accumulation into the parasite when chemically 
combined (via a sigma bond) with the ligands.  Furthermore it is not intended that the 
compounds should need to be metabolised for action, i.e. their mode(s) of action should 
remain unchanged in the derivatized form.  It would be preferable to derivatize the 
ligands, 8-HQ, 1,10-phen and terpy with D-adenosine, this isomer is extremely 
expensive, thus derivatization with L-adenosine will be undertaken instead as proof of 
concept.   While the idea of using these carriers for drug delivery is itself not novel, the 
use of pantothenic acid and adenosine to deliver the selected ligands into the parasite 
appears to be previously unreported.  Furthermore the covalent linking of these carriers 
to the ligands is also unreported. 
 
While it is clear that P.f. needs both these nutrients, pantothenic acid and adenosine (the 
D- or L-isomer), their usefulness as drug delivery pathways remains to be investigated.  
Whether they can increase the activity of antimalarial compounds would be of 
significant interest both for current drugs and for the development of new drugs.  It is 
the intention here to link both of these compounds to the ligands already discussed (8-
HQ, 1,10-phen and terpy), and to determine if any appreciable increase in toxicity is 
conferred on the ligands.  This will make use of the ‘Trojan horse’ type strategy, by 
modifying the ligands from Chapter 2, according to the synthetic schemes in the 
Chapter 4.  It is hoped that the parasite’s requirement for this solute will increase the 





Synthetic Design and Results 
4.1 Synthesis of Complexes 
As part of the planned research it was necessary to synthesize the complexes of each of 
the ligands.  These were synthesised according to the relevant established 
procedures.152, 153 
 
The 8-HQ complexes of copper and iron were made according to the procedures 
described in by Welcher.152  However since these complexes were not soluble in water, 
DMSO, DMF, acetone, ethanol, methanol or THF could therefore not be tested.  As 
these were the two metals of most significance to 8-HQ, the synthesis of complexes was 
discontinued. 
 
Similarly the 1,10-phen complexes were synthesized according to literature methods.153  
These complexes (made as the ClO4- salts) also demonstrated a total lack of solubility 
(copper and iron complexes) and thus this work was also discontinued. 
 
The terpy complexes of platinum,154 gold,155 copper,156 iron157 and palladium,158 (Figure 
4.1.1), were all synthesized according to previously established methods.  Where 
possible the synthesis was confirmed by NMR studies, IR and high resolution mass 
spectrometry (the spectra may be seen in the appendix).  In general the synthesis 
proceeded as described in the relevant literature, however the palladium terpy complex 



































Figure 4.1.1 Structures of terpy complexes synthesized and tested (counterions excluded from 
structures). 
 
Table 4.1.1 1H Chemical shifts for terpy complexes. 
Chemical shift/ppm (multiplicity, integration)i 
Proton 
29 30 33 63 
H1 7.83 (m, 2H) 8.89 (dd, 2H) 8.77 (dd, 2H) 8.72 (dd, 2H) 
H2 7.30 (m, 2H) 7.95 (m, 2H) 7.60 (m, 2H) 7.88 (m, 2H) 
H3 8.68 (m, 2H) 8.51 (td, 2H) 8.15 (m, 2H) 8.46 (td, 2H) 
H4 8.61 (m, 2H) 8.64 (m, 2H) 8.49 (d, 2H) 8.64 (m, 2H) 
H5 8.45 (m, 2H) 8.64 (m, 2H) 8.71 (d, 2H) 8.64 (m, 2H) 
H6 7.93 (m, 1H) 8.64 (m, 1H) 8.15 (m, 1H) 8.64 (m, 1H) 
                                                 
i 1H NMR spectra collected in DMSO-d6. 
 
The 1H NMR spectra of the platinum, gold and palladium complexes (Table 4.1.1) all 
demonstrate downfield proton shifts, as one would expect, due to the donation of the 
nitrogen atoms lone pairs for coordinative bonding to the respective metal centres.  
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NMR spectra for the copper and iron complexes could not be obtained due to their 
paramagnetic nature. 
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The synthetic procedure for this work was started by preparing the two targeting agents, 
pantothenic acid 59 and 5'-chloro-adenosine.  As will be described later 5'-chloro-
adenosine did not facilitate any desired coupling and was thus replaced with the more 
















Figure 4.2.1 Numbering of pantothenic acid. 
 
The two targeting agents, pantothenic acid and 5'-carboxylic-acid-adenosine, were 
prepared from calcium pantothenate and adenosine respectively.  Pantothenic acid was 
prepared by eluting a solution of the hemi-calcium salt through an ion exchange resin, 
and the acid was isolated in quantitative yield.  It was found that removal of the solvent 
(water) had to be done by lyophilization as the use of heat resulted in the formation of 
unwanted impurities observed in the NMR spectra (1H and 13C).  The chemical shifts for 




Table 4.2.1 1H Chemical shifts for pantothenic acid, 59. 
Chemical shift/ppm (multiplicity, integration)i 
Proton 
59 
H1,7 3.39 (m, 3H) 
H2 3.28 (m, 1H) 
H3 0.81 (s, 3H) 
H4 0.77 (s, 3H) 
H5 3.87 (s, 1H) 
H8 2.52 (t, 2H) 
                                                 
i 1H NMR spectrum collected in D2O. 
 
The synthetic scheme for the synthesis of 66 is seen in Figure 4.2.2.  The synthesis 
involves the protection of the alcohol groups on the nucleoside,160 followed by 































































Figure 4.2.2 Synthetic route for 5'-carboxylic-acid-adenosine, 66. 
 
This synthesis proceeded without any difficulties and was easily tracked by 1H NMR, 
see Table 4.2.2.  Protection of adenosine, resulting in 64, is easily confirmed by the 
appearance of the two singlets at 1.52 ppm and 1.31 ppm, integrating for three protons 
each, corresponding to H11 and H12 respectively.  At the same time the signals due to the 
previously unprotected –OH groups (5.51 ppm and 5.24 ppm) are no longer seen 
(adenosine 1H spectrum not shown).  Similarly the oxidation step can be confirmed by 
the loss of the two protons signals H8 and H9.  The final deprotection step is confirmed 
by the disappearance of protons due to H11 and H12.  Due to the untidiness of the 
spectrum in pure DMSO, D2O was added, resulting in the complete disappearance of 
the signal due to H3, and any of the –OH groups.  However a COSY correlation (in 
DMSO alone, COSY spectrum not shown) is still observed between these –OH protons 
and H5 and H6. 
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Table 4.2.2 1H Chemical shifts for 5'-carboxylic acid synthesis 66. 
Chemical shift/ppm (multiplicity, integration)i 
Proton 
64 65 66 
H1 8.33 (s, 1H) 8.23 (s 1H) 8.68 (s, 1H) 
H2 8.14 (s 1H) 8.07 (s, 1H) 8.41 (s, 1H) 
H3 7.35 (s 2H) 7.26 (s, 2H) Displaced by D2Oii 
H4 6.11 (d, 1H) 6.31 (s, 1H) 6.07 (d, 1H) 
H5 5.33 (dd, 1H) 5.52 (dd, 1H) 4.52 (dd, 1H) 
H6 4.95 (dd, 1H) 5.45 (d, 1H) 4.46 (d, 1H) 
H7 4.20 (m, 1H) 4.67 (d, 1H) 4.32 (dd, 1H) 
H8,9 3.54 (m, 2H) - - 
H10 5.24 (t, 1H) - - 
H11 1.52 (s, 3H) 1.51 (s, 3H) - 
H12 1.31 (s, 3H) 1.34 (s,3H) - 
                                                 
i 1H NMR spectra collected in DMSO-d6. 
ii D2O was added to produce a neater spectrum. 
 
8-Hydroxyquinoline and 1,10-Phenanthroline Derivatives 
 
Having identified both the ligands and the targeting agents to be studied, several initial 
synthetic schemes were proposed.  The original synthetic design for the derivatized 
versions of 8-HQ and 1,10-phen is outlined in Figure 4.2.3 and Figure 4.2.4 
respectively.  The approach of making an aromatic amino derivative of each of the 


































Figure 4.2.3 Proposed synthetic scheme for derivatives of 8-HQ. 
 
































Figure 4.2.4 Proposed synthesis for derivatives of 1,10-phen. 
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In each of these synthetic schemes some of the reactions were found to render very poor 
yields or no desired product at all.  For example the reactions of 5-amino-8-HQ 67, and 
5-amino-1,10-phen 71, with 5'-chloro-adenosine, were both found to be non-reactive 
(monitored by LC-MS) under a variety of conditions (including temperature, solvents 
and bases).  Both of these compounds also demonstrated limited reactivity with 
pantothenic acid as well.  This is likely due to the electron withdrawing effect of ring-
bound nitrogen atoms, resulting in a drop of nucleophilicity of the amine at the five 
position on each of the compounds.161, 162  Previous reactions where amines have been 
coupled with 5'-chloro-adenosine, were achieved under extreme conditions (a bomb 
reactor163 or extended periods of time).164  The literature procedures for purification of 
the products were also extensive, involving both preparative HPLC, the use of an ion 
exchange resin and resulted in yields around 50%. 
 
In response to the poor reactivity observed here and the limited number of reported 
reactions for the amine derivatized ligands, 67 and 71, it was decided to adapt the 
synthetic scheme.  These new schemes included a spacer (or bridge) between the 
original ligands and the targeting agents.  This would reduce possible steric interactions 
that could hinder the reactivity.  Furthermore a spacer would break conjugation, 
reducing the electron withdrawing effects of the ring-bound nitrogen atoms, increasing 
the nucleophilicity of the ligands.  A spacer also serves to keep the targeting agent and 
ligand chemically and electronically separate, a characteristic which may be 
advantageous biologically.  Several different spacers were considered including 3-
bromopropylamine and glycine, 74.  Attempts to couple 3-bromopropylamine with 5'-
chloro-adenosine were unsuccessful, these again involved various bases, solvents and 
heating methods (conventional or microwave).  Similarly attempts to couple N-
protected 3-bromopropylamine with either 67 or 71 were unsuccessful. 
 
Ultimately glycine 74 was introduced as the spacer.  Glycine was first N-protected using 
the t-BOC group to give 75 (Figure 4.2.5, chemical shifts in Table 4.2.3), and then 
reacted in large excess (16 equivalents converted to the anhydride in situ using DCC, a 
method which has only recently been reported)165 with each of the two ligands, to give 
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76 and 80 respectively.  Using EDC as a coupling reagent was also successful, but 
separation of the coupling reagent from the product proved difficult.  The glycine-




















Figure 4.2.5 Linker used for 8-HQ and 1,10-phen derivatives (both glycine, 74). 
 
Table 4.2.3 1H Chemical shifts for N-BOC-glycine, 75.166 
Chemical shift/ppm (multiplicity, integration)ii 
Protoni 
75 
H1,E&Z 3.93 (m, 2H) 
H2,E 6.70 (b, 0.33H) 
H2,Z 5.06 (b, 0.67H) 
H3 1.43 (s, 9H) 
                                                 
i 75 exists in both E and Z conformations, and thus gives a slightly complicated proton spectrum. 
ii 1H NMR spectrum collected in CDCl3. 
 
Coupling of the intermediate ligands 77 and 81 with 5'-chloro-adenosine, was again 
either low yielding or produced no desired target compound.  Following these results 
the general reactivity of 5'-chloro-adenosine was investigated.  For this purpose 
phenylethylamine was used as a synthetic mimic for the ligands.  It was found under 
various conditions (conventional heating or microwave heating) and using a variety of 
solvents, that this compound, 5'-chloro-adenosine, had limited reactivity.  Therefore it 
was decided to replace 5'-chloro-adenosine, with the more reactive, 5'-carboxylic-acid-
adenosine 66, the synthesis of which is described in Figure 4.2.2.  The final synthetic 
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routes for the derivatized versions of 8-HQ and 1,10-phen are described in Figure 4.2.6 
and Figure 4.2.7. 
 
At this point each of the targeting agents was reacted with these newly functionalized 
ligands, giving compounds 78 and 79 (in the case of 8-HQ), and 82 and 83 (1,10-phen) 
respectively (Figure 4.2.6 and Figure 4.2.7).  For the final steps it should be noted that 
tracking of these reactions was not possible using normal phase TLC plates.  Hence LC-
MS was the preferred method of analysis used to track the reaction of each ligand with 
each of the targeting agents.  Coupling of the amines with pantothenic acid, 59, was 
achieved using diphenylphosphoryl azide (DPPA), a general procedure well established 
in literature.167-170  In the case of coupling with 66, o-benzotriazole-N,N,N',N'-

















































































Figure 4.2.6 Synthetic route for derivatization of 8-HQ with pantothenic acid (A) or adenosine (B). 
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The 1H chemical shifts for the synthesis of the 8-HQ derivatives 76-79, are reported in 
Table 4.2.4.  The addition of 75 to 8-HQ is monitored by the appearance of a doublet 
(2H) at 3.81 ppm, due to H7 (H2 on 75) and the singlet (9H) at 1.40 ppm due to H9 (H3 
on 75).  Deprotection with TFA affords the loss of this singlet and a downfield shift for 
the amide H6 and the amine H8.  The addition of either 59 or 66 results in a spectrum 
which appears almost as an overlap of the two spectra of the precursors (i.e. either 59 
and 77 or 66 and 77) thus the assignment of the 1H signals for 78 and 79 is fairly trivial. 
 
Table 4.2.4 1H Chemical shifts for synthesis of 8-HQ derivatives. 
Chemical shift/ppm (multiplicity, integration)i 
Proton 
76 77 78 79 
H1 8.85 (dd, 1H) 8.93 (d, 1H) 8.91 (s, 1H) 8.89 (d, 1H) 
H2 7.56 (m, 1H) 7.69 (dd, 1H) 7.68 (dd, 1H) 7.63 (dd, 1H) 
H3 8.31 (dd, 1H) 8.52 (d, 1H) 8.44 (d, 1H) 8.41 (d, 1H) 
H4 7.39 (d, 1H) 7.52 (d, 1H) 7.44 (d, 1H) 7.45 (d, 1H) 
H5 7.05 (d, 1H) 7.16 (d, 1H) 7.13 (d, 1H) 7.09 (d, 1H) 
H6 9.76 (s, 1H) 10.35 (s, 1H) 9.87 (s, 1H) 9.94 (s, 1H) 
H7 (and A-H7) 3.81 (d, 2H) 3.92 (m, 2H) 3.97 (d, 2H) 4.21 (m, 3H) 
H8 7.12 (t, 1H) 8.17 (b, 2H) 8.35 (t, 1H) 9.27 (s, 1H) 
H9/P-OH 1.40 (s, 9H) - 8.14 (s) - 
P-H1,2,7/A-H1 - - 3.22 (m, 4H) 8.51 (s, 1H) 
P-H3/A-H2 - - 0.79 (s, 3H) 8.26 (s, 1H) 
P-H4/A-H3 - - 0.78 (s, 3H) - 
P-H5/A-H4 - - 3.69 (s, 1H) 6.03 (d, 1H) 
P-H6/A-H5 - - 7.76 (t, 1H) 4.67 (dd, 1H) 
P-H8/A-H6 - - 2.41 (m, 2H) 4.46 (s, 1H) 
                                                 
i 1H NMR spectra collected in DMSO-d6, P denotes pantothenate peaks and A denotes adenosine peaks. 
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Figure 4.2.7 Synthetic route for derivatization of 1,10-phen with pantothenic acid (A) or adenosine 
(B). 
 
The synthetic route for 1,10-phen began by conversion of the ligand to a nitro 
compound, which was then reduced to an amine (1% Pd/C) which then opened up 
synthetic routes to the intermediate and target ligands, the 1H NMR shifts of which are 
reported in Table 4.2.5.  Conversion of 1,10-phen to 70 was done under harsh 
conditions (the reaction only proceeded at 160–170 °C in the presence of 98% H2SO4  
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Table 4.2.5 1H Chemical shifts for synthesis of 1,10-phen derivatives. 
Chemical shift/ppm (multiplicity, integration)i 
Proton 
70 71 80 81 82 83 
H1 9.35 (dd, 1H) 9.18 (dd, 1H) 9.12 (dd, 1H) 9.30 (d, 1H) 9.13 (d, 1H) 9.13 (d, 1H) 
H2 7.80 (m, 1H) 7.63 (dd, 1H) 7.80 (m, 1H) 8.11 (m, 1H) 7.83 (dd, 1H) 7.83 (dd, 1H) 
H3 9.02 (dd, 1H) 8.26 (dd, 1H) 8.61 (d, 1H) 8.98 (m, 1H) 8.60 (d, 1H) 8.66 (d, 1H) 
H4 8.69 (s, 1H) 6.93 (s, 1H) 7.20 (s, 1H) 8.44 (s, 1H) 8.12 (s, 1H) 8.13 (s, 1H) 
H5 8.42 (dd, 1H) 7.96 (dd, 1H) 8.45 (d, 1H) 8.98 (m,1H) 8.46 (d, 1H) 8.46 (d, 1H) 
H6 7.80 (m, 1H) 7.48 (dd, 1H) 7.75 (m, 1H) 8.11 (m, 1H) 7.76 (m, 1H) 7.74 (dd, 1H) 
H7 9.29 (dd, 1H) 8.92 (dd, 1H) 9.03 (dd, 1H) 9.19 (d, 1H) 9.05 (d, 1H) 9.04 (d, 1H) 
H8 - 4.25 (b, 2H) 10.15 (s, 1H) 10.91 (s, 1H) 10.20 (s, 1H) 10.30 (s, 1H) 
H9 (and A-H7) - - 3.93 (d, 2H) 4.08 (d, 2H) 4.08 (d, 2H) 4.28 (m, 3H) 
H10 - - 8.13 (s, 1H) 8.29 (b, 2H) 8.41 (t, 1H) 9.52 (s, 1H) 
H11 - - 1.48 (s, 9H) - - - 
P-OH - - - - 8.15 (s) - 
P-H1,2,7/A-H1 - - - - 3.25 (m, 4H) 8.44 (s, 1H) 
P-H3/A-H2 - - - - 0.81 (s, 3H) 8.16 (s, 1H) 
P-H4/A-H3 - - - - 0.79 (s, 3H) 7.42 (s, 2H) 
P-H5/A-H4 - - - - 3.71 (s, 1H) 6.03 (d, 1H) 
P-H6/A-H5 - - - - 7.76 (m, 1H) 4.71 (dd, 1H) 
P-H8/A-H6 - - - - 2.43 (m, 2H) 4.46 (s, 1H) 
                                                 
i All 1H NMR spectra collected in DMSO-d6, except 70 and 71 which were collected in CDCl3, P denotes 
pantothenate peaks and A denotes adenosine peaks. 
 
and 63% HNO3, lower concentrations of nitric acid did not result in nitration).171  The 
nitration of 1,10-phen to 70 is easily confirmed by the downfield singlet H4 (1H) 
appearing at 8.69 ppm.  Reduction of the nitro group to an amine, 71, results in the 
singlet shifting to 6.93 ppm and the appearance of a broad peak (2H) at 4.25 ppm.  It 
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should be noted that most synthetic steps (for both 8-HQ and 1,10-phen) were 
investigated using 71, because of the relatively simple synthesis and low cost of reaction 
materials (with the exception of the catalyst, which can be recycled). 
 
Coupling of 71 with 75  to give 80, was (as in the derivitization of 8-HQ) monitored by 
the appearance of a doublet (2H) at 3.93 ppm and a singlet (9H) at 1.48 ppm.  
Furthermore the amide proton H8 is dramatically shifted downfield from 4.25 ppm to 
10.15 ppm.  Deprotection of the glycine amine was confirmed by the disappearance of 
the singlet at 1.48 ppm, assigned to the t-BOC protons (H11). 
 
As in the case of 8-HQ the proton spectra of the final derivatized ligands of 1,10-phen 
appear almost as an overlay of the two precursors in each case, i.e. 80 with 59 or 80 
with 66.  The most dramatic shift is observed for H8, which moves upfield by 
approximately 0.7 ppm (82) and 0.6 ppm (83) in each case. 
 
The work has resulted in the successful synthesis of four novel compounds, the 
adenosine and pantothenic acid derivatives of 8-HQ and 1,10-phen (compounds 78, 79, 
82 and 83), all previously untested for their activity against Plasmodium falciparum.  
However while the synthesis of each of these molecules was successful, their low yields 
(approximately 20% in each case) and the difficulty of the procedures involved in 
purifying them would likely make these compounds financially unviable as commercial 
antimalarial drugs. 
 
2,2':6',2'' Terpyridine Derivatives 
 
The synthetic route for terpy was similar to that for 1,10-phen: to synthesize an amino 
derivative 85 and then couple this directly with the targeting agents.  The first step of 
this plan was abandoned, as attempts to convert the chloro-terpy derivative 84 to 85, 
according to the method of Mutai et al.172 were unsuccessful (Figure 4.2.8).  Other 
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authors have previously reported synthetic difficulty with this reaction.173  The step 
involving coupling with 5'-chloro-adenosine, was also abandoned due to the poor 












































Figure 4.2.8 Proposed synthetic scheme for derivatives of terpy. 
 
Thus as with 8-HQ and 1,10-phen a different synthetic route had to be established.  
While glycine proved to be a successful solution in the cases of 8-HQ and 1,10-phen, 84 
would first have to be converted to some form of amine.  The solution to this was 
provided by Senechal-David et al.,173 who have demonstrated that 1,3-diaminopropane 
reacts well with 84.  For the synthetic procedure here 1,2-diaminoethane 88 (Figure 
4.2.9) was used instead to give the aminoethyl-amino-terpy derivative 89.  This reaction 
provided both a site for coupling with the targeting agents (an amine), as well as a 
spacer, in one synthetic step.  This derivative, 89, was then reacted with each of the 
targeting agents, 59 and 66, to give 90 and 91, respectively (using the same conditions 




























































































Figure 4.2.9 Synthetic route for derivatization of  terpy with pantothenic acid (A) or adenosine (B). 
 
A comparison of the 1H NMR spectra of the terpy derivatives is provided in Table 4.2.6.  
The successful synthesis of 89 (at a slightly higher yield of 50% compared with other 
target molecules) is confirmed by the appearance of the two additional signals at 3.41 
ppm (2H) and 3.00 ppm (2H) due to the ethyl protons on the product.  Further 
confirmation is the appearance of an –NH- triplet at 4.86 ppm (1H), corresponding to 
H6.  Reaction with 59 gave 90.  The 1H NMR spectrum of 90 is slightly more 
complicated than that of the 8-HQ and 1,10-phen derivatives of pantothenic acid.  This 
is due to some overlap between H7 and H8 from terpy and H1, H2 H7 of 59, leading to 
multiplets in these regions, however this is easily observed due to the correspondence to 
both terpy carbons and pantothenic acid carbons in the HSQC spectrum.  The spectrum 
however again, appears much like a combination of the spectra of the two starting 
compounds. 
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Table 4.2.6 1H Chemical shifts for synthesis of terpy derivatives. 
Chemical shift/ppm (multiplicity, integration)i 
Proton 
89 90 91 
H1 7.28 (ddd, 2H) 7.15 (m, 2H) 7.51 (m, 1H) 
H2 7.80 (ddd, 2H) 7.59 (m,2H) 8.00 (m, 2H) 
H3 8.65 (ddd, 2H) 8.60 (m, 2H) 8.73 (m, 2H) 
H4 8.59 (dt, 2H) 7.99 (m, 2H) 8.49 (m, 2H) 
H5 7.68 (s, 2H) 7.99 (m, 2H) 7.68 (s, 2H) 
H6 4.86 (t, 1H) 7.33 (t, 1H) - 
H7 3.41 (m, 2H) 3.38 (m, 2H) 3.50 (t, 2H) 
H8 3.00 (m, 2H) 3.38 (m, 2H) 2.90 (t, 2H) 
H9 - 8.38 (s, 1H) 9.29 (s, 1H) 
P-OH/ A-H7 - - 4.20 (s, 1H) 
P-H1,2,7/A-H1 - 3.38 (m, 4H) 8.37 (s, 1H) 
P-H3/A-H2 - 0.82 (s, 3H) 8.23 (s, 1H) 
P-H4/A-H3 - 0.78 (s, 3H) 7.41 (s, 2H) 
P-H5/A-H4 - 3.89 (s, 1H) 5.95 (d, 1H) 
P-H6/A-H5 - - 4.63 (d, 1H) 
P-H8/A-H6 - 2.44 (t, 2H) 4.35 (s, 1H) 
 
                                                 
i 1H NMR spectra collected as follows: 89 in CDCl3, 90 in D2O and 91 in DMSO-d6, P denotes 
pantothenate peaks and A denotes adenosine peaks. 
 
The spectrum of 91 (once more only a low yield of 20% could be achieved) is easily 
elucidated due to the lack of overlapping of proton signals due to 66 and 91.  The only 
problem associated with this spectrum again is the reduced signals of H7 and H8 due to 
the associated suppression of the water peak.  As with the synthesis of earlier adenosine 
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derivatives the proton NMR spectrum is essentially a simple combination of each of the 
precursors. 
The synthesis of all derivatives has been confirmed using NMR and MS methods.  Due 
to the often poor reactivity of the compounds the synthetic routes were adapted to 
include a spacer between the ligands and the targeting agents.  This ultimately allowed 
for the ligands and targeting agents to be covalently linked, resulting in six novel 
compounds (78, 79, 82, 83, 90 and 91).  This type of structure may also confer other 
advantages by keeping the ligands and the targeting agents chemically separate, a 





Antimalarial Testing Results and Discussion 
5.1 Baseline Antimalarial Activities 
Activity of Transition Metal Ions 
 
As part of examining the roles of metals in this study it was important to first determine 
the background activities of the transition metals of interest.  The ions investigated in 
this study included Cu2+ (because of its previous use with 8-HQ95, 96 and 1,10-phen101), 
Fe3+ (for its previous use with 8-HQ85, 95, 96), Au3+ and Pt2+ (for their previous use with 
terpy).123, 133, 136  The antimalarial activities of these transition metal ions were 
previously unreported.  The toxic affect of each of the metals was determined using 
their chloride salts.  These results can be seen in Table 5.1.1. 
 
Table 5.1.1 Antimalarial activity of transition metalsi (against strain 3D7ii). 
Metal Salt IC50/μM 
CuCl2 35.2 




                                                 
i All metal salts were dissolved in deionised H2O. 
ii The 3D7 is a chloroquine susceptible strain of the malaria parasite. 
iii PdCl2 preicpitated out during testing. 
 
With the exception of the platinum salt, the toxicities of the metals are quite low, and as 
one might expect in a biological system, the toxicity increases in the order Fe3+ < Cu2+ < 
Au3+ < Pt2+.  With these values established it was decided that the metals would have 
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minimal toxic effect at concentrations of 0.5 μM (as free metals in the growth medium).  
The extremely low activity of iron is likely due to the formation of iron oxides at the 
testing pH, approximately pH 7.  Thus this concentration was used when investigating 
the ability of the various metals, when uncomplexed, to potentiate the activities of the 
each of the ligands, 8-HQ, 1,10-phen and terpy. 
 
Activity of Ligands 
 
The aim of studying 8-HQ was to bring clarity to the currently published literature.  
Some authors have reported micromolar activity,88 while another has reported 
nanomolar acvivity.91  The role played by metals in the activity of this ligand will also 
be investigated. 
 
Initial research was done on the activity of several 8-HQ derivatives, to determine if 
there were any simple structural alterations which might affect activity.  The 
compounds in Figure 5.1.1 were tested (for motivation see Chapter 2).  The results of 






















Figure 5.1.1 Compounds tested for their ability to inhibit β-haematin formation. 
 
Table 5.1.2 Antimalarial activity of selected ligands (against strain 3D7). 
Ligand IC50/μM 
Chloroquine 0.022 
8-HQ (1) 2.4 
2-methyl-8-HQ (2) 47 
5-amino-8-HQ (67) 1.0 
1,10-phen (16) 0.99 
5-amino-1,10-phen (71) 0.94 
Terpy (29) 0.85 
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The results obtained here are in agreement with those previously reported by Scheibel 
and his coworkers in their series of papers,88 and not with those of Biswas.91  The 
activity of 8-HQ (and its derivatives in general) is in the micromolar, and not 
nanomolar, range of activity and is less active than chloroquine (several cloroquine 
resistant and susceptible strains were tested, including 3D7, by Biswas91 under the same 
conditions as those used in this study).  
 
Furthermore it is evident here that the activity of 2-methyl-8-HQ is lower (by one order 
of magnitude), while the 5-amino-8-HQ species has comparable activity with that of 8-
HQ itself.  The lower activity of 2-methyl-8-HQ suggests that the mode of action of 8-
HQ may require some form of complexation, exhibiting its antimalarial effect either as a 
toxic metal complex (as suggested in the reported antibacterial studies)94 or by blocking 
the metal site on a metalloprotease (as has been suggested for 1,10-phen)118.  It is also 
evident that derivitization at the five position has little effect on the activity of 8-HQ.  In 
light of this result, 5-amino-8-HQ was used for all other studies as it would be the 
starting point for the synthesis of the target ligands. 
Similarly the activities of 1,10-phen and 5-amino-1,10-phen were of the same order of 
magnitude.  The activities found here, approximately 1 μM, are an order of magnitude 
higher than that reported by Kitjaroentham et al.118 (24 μM) who proposed that the 
mode of action was via the inhibition of a metalloprotease involved in RBC invasion.  
Again because of the similar activities of 5-amino-1,10-phen and 1,10-phen the amino 
version was used for further metal-ligand studies. 
 
Of the three ligands terpy demonstrated the highest activity, 0.85 μM (although it is of 
the same order of magnitude as both 8-HQ and 1,10-phen).  It appears that this is the 
first reported testing of this ligand against malaria. 
 
With the background of activities of both the metal ions, and the ligands established, it 
became possible to investigate how increased free metal concentrations might affect 
their activities. 
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5.2 Antimalarial Activities of Ligands with Metals 
Activity of Ligands with Metal-Enhanced Growth Medium 
 
The second part of this study was aimed at determining whether increasing the metal 
concentration in the growth medium would potentiate the activity of any of the ligands.  
With the baseline toxicities of the metals determined, a background concentration of 0.5 
μM was used.  These results are reported in Table 5.2.1. 
Table 5.2.1 Activities of ligands in presence of free metals. 
Ligand (Metal Ion) IC50/μM 
5-amino-8-HQ (Au3+) 0.72 
5-amino-8-HQ (Cu2+) 0.85 
5-amino-8-HQ (Fe3+) 0.87 
5-amino-8-HQ (Pt2+) 0.73 
5-amino-1,10-phen (Au3+) 0.91 
5-amino-1,10-phen (Cu2+) 0.86 
5-amino-1,10-phen (Fe3+) 0.87 
5-amino-1,10-phen (Pt2+) 0.73 
terpy (Au3+) 2.27 
terpy (Cu2+) 1.0 
terpy (Fe3+) 10 < 
terpy (Pt2+) 1.0 
 
In general the increased free-metal concentration had no observable effect on the 
activities of the ligands.  Only a very slight increase in activity was ever observed but 
none was significant enough to suggest that any of the tested metals are involved in the 
mode of action of 5-amino-8-HQ, 5-amino-1,10-phen or terpy. 
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These results have three immediate implications.  Firstly, it suggests that the mode of 
action of these ligands does not involve the formation of a toxic metal complex in situ.  
If this were the mode of action, one would expect increased activity with an increase in 
background metal concentration (as observed in antibacterial studies96).  Second, the 
results suggest that none of the ligands act by sequestration of metals (this result is 
limited to those tested here, iron, copper, gold and platinum) away from the parasite, 
since the toxic effect is not reversed by the addition of these free metals.  Third, this 
lack of reversal also suggests that the mode of action is not via coordination to a 
metalloenzyme.118  The free metals should be as easily complexed as enzyme bound 
metals thus decreasing the amount of free ligand available to block parasite-enzyme 
metal sites. 
 
An exception to this case is that of terpy with free iron.  The activity of terpy with free 
iron in solution (10 μM < IC50) is far worse than that observed for terpy alone (1.0 μM, 
a more than ten-fold reduction in activity) and suggests that free iron is antagonistic 
towards the activity of terpy.  This is likely due to complexation of free iron by terpy 
which either prevents its mode of action or alters uptake of the ligand or its 
transportation into the parasite.  Since the other metals do not inhibit the activity to such 
an extent it seems logical to suggest that the complex formed in situ is in fact preventing 
the mode of action by preventing its transport into the parasite.  This is possibly due to 
the relatively high effective charge density associated with the terpy-iron (III) complex.  
The ligand also shows reduced activity in the presence of free gold (III), IC50 2.3 μM, 
although it is not as pronounced as found in the case of iron (III).  This could be due to 
the larger size of the gold (III) ion, leading to a lower effective charge density.  Free 
copper and platinum, both having charges of 2+, showed no observable effect on the 





Activity of Ligand-Metal Complexes 
 
With the metals, the ligands, and the ligands with metal enhanced growth medium 
tested, the pre-made complexes remained to be examined.  To achieve this, complexes 
of the ligands with each of the metals were made (see Chapter 4).  For 8-HQ and 1,10-
phen the complexes made were insoluble and their activities therefore could not be 
assessed (results not shown).  However the complexes of terpy were successfully 
synthesised, soluble and tested.  The antimalarial activities of the terpy complexes are 
reported in Table 5.2.2. 
Table 5.2.2 Antimalarial activities of terpy complexes (against strain 3D7). 
Complex IC50/μM 
[Pt(terpy)Cl]Cl (30) 0.41 
[Au(terpy)Cl]Cl2 (33) 0.30 
[Cu(terpy)Cl]Cl (61) 0.52 
Fe(terpy)Cl3 (62) 0.63 
[Pd(terpy)Cl]Cl (63) 0.71 
 
Each of the metal complexes has slightly better activity than terpy as a free ligand (IC50 
= 0.85 μM).  The gold-terpy demonstrates the highest activity, approximately three fold 
that seen for the ligand on its own.  If one looks at these results from the perspective of 
the activity of terpy, it appears as if the metals do little to enhance the activity of the 
ligand.  Furthermore it suggests that metal complexation is not essential for terpy to 
exhibit its antimalarial cytotoxic effect.  In cancer studies it has predominantly been 
suggested that metals are required for terpy to exhibit activity, 128, 136-140 although a few 
papers have shown that terpy and some derivatives have similar or even higher 
anticancer activity than their complexes.131, 141, 142  It is often the case that the ligands in 
these studies are not tested for any intrinsic activity. 
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However these results can also be seen from the perspective of the metals.  For each of 
the metals the activity has been increased significantly.  A comparison of the acitivities 
of the metal salts and the terpy-metal complexes is shown in Table 5.2.3. 
Table 5.2.3 Comparison of the activities of metals and their complexes with terpy. 
Metal Salt IC50/μM Complex IC50/μM 
HAuCl4 23.5 [Au(terpy)Cl]Cl2 0.30 
CuCl2 35.2 [Cu(terpy)Cl]Cl 0.52 
FeCl3 20 x 103 Fe(terpy)Cl3 0.63 
K2PtCl4 2.41 [Pt(terpy)Cl]Cl 0.41 
PdCl2 ND [Pd(terpy)Cl]Cl 0.71 
 
All the metals show enhanced activity when in the complexed form.  The increase is 
most pronounced for iron (approximately 30 000 fold), followed by gold (approximately 
78 fold), copper (approximately 68 fold) and platinum (approximately 6 fold).  This 
increase in activity for the metals is quite possibly due to their enhanced transportation 
into the parasite when in the complexed form.  No direct measurement of the 
transportation (or uptake) of the metals was performed.  It has however been 
demonstrated before that ligands are capable of facilitating the transport of metal ions 
into the parasite.85  Thus it could well be that the ligand allows more of the metal ions to 
reach their active site(s) in the parasite. 
 
It is interesting to note that the results are open to interpretation from either the ligands’ 
perspective (which suggests only a marginal increase in activity) or from the metals’ 
perspective (which then suggests a significant increase in activity).  If the exact mode of 
action of the ligand, the metals and the complexes were all known one could perhaps 
determine which of these points holds more scientific weight.  It is of course quite 
possible as well that they all act via totally different mechanisms.  In light of this it 
became essential to test whether any of the compounds demonstrated an ability to 
inhibit β-haematin formation, according to the assay of Egan et al..28 
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Antimalarial Activities of Derivatized Ligands 
 
The goal of this part of the study was to determine if the activity of the various ligands 
could be improved by covalently linking them to nutrients for which iRBCs have a 
higher or exclusive affinity (described in Chapter 3).  Hypothetically these new 
compounds (synthetic procedures described in Chapter 4 and 6) should benefit from 
enhanced transport into the parasite, hence a higer local concentration, resulting in 
better acivity.  The antimalarial testing results for the derivitized ligands, 78, 79, 82, 83, 
90 and 91, (as well as the intermediates, 77, 81 and 89) are reported in Table 5.2.4. 
 
Table 5.2.4 Antimalarial activities of intermediates and derivatized ligands (against strain D10).i 
Ligand IC50/μM 
Chloroquine 0.016 
8-HQ-gly (77) 29 
8-HQ-Pant (78) 100< 
8-HQ-Ade (79) 100< 
1,10-Phen-Gly (81) 29 
1,10-Phen-Pant (82) 135 
1,10-Phen-Ade (83) 2.4 
Ethylamino-Terpy (89) NDii 
Terpy-Pant (90) 5.1 
Terpy-Ade (91) NDii 
                                                 
i Due to circumstances the later compounds were tested against the D10 strain of malaria and not the 3D7 
strain as was used for earlier samples.  Both strains are chloroquine susceptible and chloroqine was used 
as a control in both cases.  The chloroquine results are similar in each case (0.022 μM, 3D7, and 0.016 
μM, D10). 
ii Results could not be determined due to interfering absorbance by the compounds.  The assay makes use 
of a colourimetric detection method. 
 
 87
The activities found for the derivatives are all lower than those found for the parent 
ligands.  However there are no clear trends for either of the pantothenic acid derivatives 
or the adenosine derivatives.  In the case of 8-HQ, the introduction of the targeting 
agents has severely reduced the activity of the ligand, dropping from 2.4 μM to > 100 
μM.  For 1,10-phen we observe that the adenosine derivative, 83, has activity in the 
same region as 1,10-phen, while the activity of the pantothenic acid derivative, 82, is 
reduced ten fold.  In contrast however, the activity of the terpy pantothenic acid 
derivative, 90, is similar to that of terpy, while unfortunately the activity of the 
adenosine derivative, 91, could not be determined. 
 
It is apparent from the results that the targeting agents do not confer any ability to 
enhance the activity of the parent ligands.  It is particularly interesting that the activity 
of 8-HQ is so much lower once derivatized.  This suggests that either the toxicity is 
reduced by derivitization, or the molecule is no longer transported to its active site.  
However, since one of the 1,10-phen derivatives and one of the terpy derivatives each 
show activity similar to the parent ligands, a lack of transportation seems unlikely, as 8-
HQ is the smallest of the ligands (although the exact location at which the drugs exhibit 
their toxic effects is unknown and may be different). 
 
In general it is clear that the derivitization of these ligands, 8-HQ, 1,10-phen and terpy, 
have seen no benefit from being covalently linked to the targeting agents.  There are 
several possible explanations for this lack of activity: 
1) the targeting agents might no longer be recognized by the parasite’s transport 
systems; 
2) the derivitized ligands may be too big to be transported effectively; 
3) derivitization may affect the toxicity or mode of action of the ligands or 




Any one or combination of these possibilities would be sufficient to render the 
derivitization ineffective.   
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5.3 β-Haematin Inhibition Results 
As part of this study has involved discussion around the modes of action of the various 
ligands and complexes, an investigation into their ability to inhibit β-haematin 
formation was undertaken.  It has been suggested that chloroquine exhibits its 
antimalarial effect by this mode of action by preventing the spontaneous (lipid 
catalyzed) formation of haemozoin.29  A simple assay has been developed by Egan et 
al.28 and it is this method which has been used here to determine whether the 
compounds from this study do in fact inhibit β-haematin formation.  An example of an 
infrared spectrum positive for β-haematin formation and one negative for β-haematin 
formation are shown in Figure 5.3.1 and Figure 5.3.2 respectively.  The results of these 
investigations are found in Table 5.3.1. 
 
 
Figure 5.3.1 An infrared spectrum positive for β-haematin formation. 
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Figure 5.3.2 An infrared spectrum negative for β-haematin formation (chloroquine). 
 
Initially the ligands and complexes were tested.  It was suspected that these compounds 
might demonstrate some ability to inhibit β-haematin formation due to their planar 
structures.  However it has been previously reported that several 1,10-phen derivatives, 
including 5-nitro-1,10-phen did not inhibit β-haematin formation.116  This is in 
agreement with the results found here for the various 1,10-phen derivatives.  It has also 
been reported that 8-HQ does not inhibit β-haematin formation,28 again in agreement 
with the results observed in this study.  In general the results here suggest that the 
ligands do not act by inhibition of haemazoin formation in the parasite.  Similarly the 
derivatives of each of the ligands (as well as their precursors, 59, 66, 77, 81 and 89) 
showed no ability to inhibit β-haematin formation 
 
In contrast however platinum complexes, exemplified by that seen in Figure 5.3.3, have 
been reported to inhibit β-haematin formation.116  In this report by Egan et al.116 the 
ability of these complexes to inhibit β-haematin formation, was attributed to their self-
aggregating behaviour a property likely due to the planar nature of the ligand-metal 
complexes.116  Thus the complexes (of terpy) in this study were also investigated for 
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their ability to inhibit β-haematin formation.  All the terpy complexes, except that of 
copper, were found to prevent the formation of β-haematin. 
 
Table 5.3.1 Results of β haematin inhibition assays (ligands and complexes). 
Ligand or Complex β-Haematin Formation 
None + 
Chloroquine - 
 Pantothenic Acid (59) + 
Acid-Ade (66) + 
8-HQ (1) + 
8-HQ-Gly (77) + 
8-HQ-Pant (78) + 
8-HQ-Ade (79) + 
1,10-Phen (16) + 
1,10-Phen-Gly (81) + 
1,10-Phen-Pant (82) + 
1,10-Phen-Ade (83) + 
Terpy (29) + 
Ethyl-amino-terpy (89) + 
Terpy-Pant (90) + 
Terpy-Ade (91) + 
[Pt(terpy)Cl]Cl (30) - 
[Au(terpy)Cl]Cl2 (33) - 
[Cu(terpy)Cl]Cl (61) + 
Fe(terpy)Cl3 (62) - 










Figure 5.3.3 A platinum complex designed to inhibit β-haematin formation.116 
 
Having found that several of the terpy complexes inhibited β-haematin formation, it was 
decided to test the chloride salts of the metals (see Table 5.3.2).  This would resolve 
whether the ability to inhibit β-haematin formation was derived from the metals or if it 
was a new property resulting from the combination of ligand and metal.  The results 
demonstrated that the metal salts of iron, gold, platinum and palladium were capable of 
inhibiting β-haematin formation, while that of copper did not.  The prevention of β-
haematin formation is likely via the coordination of the metal centre to a propionate 
group, preventing the dimerization of haem as reported.23  While there is no direct 
evidence to support this claim it does seem the most likely means by which the metals 
would exert their action23  Thus it is suggested that the ability to inhibit β-haematin 
formation is inherent to the metals, and not a new property of the ligand-metal 
complexes.  This conclusion is supported by the fact that the only complexes which 
inhibited β-haematin formation, were those containing metals which on their own 
exhibited this property.  Furthermore copper metal does not exhibit any ability to inhibit 
β-haematin formation, and its complex with terpy, likewise does not.  The result implies 
that the β-haematin inhibiting properties of any complexes of iron, gold, platinum or 
palladium, may be due to the metals’ inherent ability to exhibit this action, and not in 
fact due to the combination of ligand(s) and metal.  However this statement can only be 
applied with certainty to this study, and may not be true for other cases, such as the 
those (of platinum) reported by Egan et al..116 
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Table 5.3.2 Results of β-haematin inhibition assays (metal salts). 







When considered as a whole the results here show that ligands which do not inhibit β-
haematin formation can have this property conferred on them by metals such as iron, 
gold, platinum and palladium.  It is also suggestive that in general ligands may act via 
different modes of action from their corresponding complexes, and furthermore that the 
ligands in the complex form may only be responsible for increasing the transport (and 
uptake) of these toxic metals into the parasite, and that the activity observed for the 
complexes is a direct result of the properties of the metal centre.  It has been interesting 
to discover, however, that copper does not demonstrate any ability to inhibit β-haematin 
formation, neither as the free metal nor in complex form.  Interestingly, the terpy-copper 
complex still shows higher activity than the free metal.  While this activity suggests that 
the complex is toxic, no hypothesis can be put forward as to why copper and its 




In general the aim of this work was to investigate the relationship between the ligands 
8-HQ, 1,10-phen and terpy and the metal ions of gold, copper, iron, platinum and 
palladium.  The secondary aim was to identify two nutrients specific to Plasmodium 
falciparum iRBCs, to covalently link these to the ligands and determine whether this 
structural alteration enhances the antimalarial activity in any way.  The final aim was to 
use the assay developed by Egan et al.28 to investigate if the studied compounds are 
capable of β-haematin inhibition, the mode of action attributed to chloroquine. 
 
In order to study the relationship between the ligands and metals several experiments 
were performed.  The background activities of each of the ligands and each of the 
metals was measured.  This appears to be the first report of the activities of the metals, 
gold, copper, iron, platinum and palladium.  Their toxicities ranged from 2.4 μM 
(platinum) to 20 mM (iron). 
 
With these background values established, the relationship between the activities of the 
ligands and the free metal concentrations in solution was investigated.  It was found that 
with the exception of iron the free metal concentration had neither an antagonistic nor 
synergistic effect on the antimalarial activity of the ligands.  High concentrations of free 
iron were antagonistic towards the activity of terpy (reducing the IC50 ten fold to 
approximately 10 μM), but had no effect on the activity of the other two ligands. 
 
Following this work it was decided to investigate whether premade ligand-metal 
complexes would behave differently from ligands administered in medium with higher 
concentrations of free metals.  For 8-HQ and 1,10-phen, the complexes of iron and 
copper which were synthesized were found to be too insoluble to permit testing.  
However in the case of terpy, complexes of each of the metals were successfully 
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synthesized and sufficiently soluble to allow testing.  This is the first apparent report of 
the antimalarial acitivity of both terpy and its complexes with the metal ions of gold, 
copper, iron, platinum and palladium.  Each of the complexes showed activity similar to 
that of the ligand alone.  All activities were in the sub-micromolar range (0.1-1 μM). 
 
The main synthetic part of this work was to covalently link the ligands (identified in 
Chapter 2) to the targeting agents (identified in Chapter 3).  This work resulted in the 
synthesis of six novel compounds 78, 79, 82, 83, 90 and 91 which were then tested for 
their antimalrial activities.  Unfortunately none of these compounds demonstrated any 
increased activity as a result of this structural modification (covalently linking the 
ligand to a malaria specific nutrient).  While some of the compounds showed much 
lower activities (78, 79 and 82), others showed activity of the same order of magnitude 
as the parent ligands (83 and 91).  Only 90 could not be determined.  Clearly the two 
nutrients selected have no benefit to confer onto the parent ligands.  This lack of 
improvement could be the result of one of several circumstances: the derivitization has 
in fact removed the toxic effect of the ligand; the targeting agents are no longer 
recognized by the parasite’s transport pathways; the ligand no longer locates where it 
exerts its effect or the actual mechanism by which the ligand acts is hindered by the 
structural alteration. 
 
As a secondary study the ability of each of the compounds to inhibit β-haematin 
formation was investigated.  While none of the ligands (basic or derivitized) showed 
any ability to inhibit β-haematin formation, many of the complexes did.  It was found 
that all of the complexes of terpy, with the exception of copper, inhibited β-haematin 
formation.  Investigations of the chloride salts of each of the metals revealed that β-
haematin inhibition was intrinsic to the metals, iron, gold, platinum and palladium but 
not copper.  Thus it is apparent that the complexes of terpy and the ligand itself, might 
well exert their toxic effects by different mechanisms.  It also became apparent that the 
ligand might serve as a transportation agent, to deliver the metals into the parasite i.e. 
that the ligand serves to enhance the activity of the metals, an idea opposite to the 
conventional perspective that metals increase the activities of ligands. 
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This work has established several results.  The ambiguity with respect to the activity of 
8-HQ has been resolved to be of the micromolar order.  The IC50 of 1,10-phen was also 
confirmed (0.99 μM) and the activity of terpy (0.85 μM) reported for the first time.  
Similarly the activities of the complexes of terpy with gold, copper, iron, platinum and 
palladium were also reported.  The novel compounds 78, 79, 82, 83, 90 and 91 were 
synthesized and tested and led to the conclusion that neither adenosine nor pantothenic 
acid conferred any enhanced activity on the ligands.  The toxicities of the metal ions 
themselves are also apparently reported here for the first time.  Furthermore it is evident 
that the ligands 8-HQ, 1,10-phen and terpy do not require any free metal ions in solution 
to exert their toxic effects.  Some interesting mechanistic discoveries were also made.  It 
was found that the metals exhibit an inherent ability to inhibit β-haematin formation 
(except copper) and that this property is conferred to complexes of the metals as well (at 
least in the case of terpy complexes).  This may well provide a path for future workers 
to develop compounds capable of β-haematin inhibition as they strive to develop new 








All solvents and reagents were obtained from Acros, Aldrich, Fluka, Merck or Alfa-
Aesar.  Unless otherwise stated, these were used without further purification.  Solvents 
(CH3CN and DMF) were dried according to the methods in Vogel.174  All other solvents 
were used without drying.  Thin-layer chromatography (TLC) was conducted on 
aluminium-backed, precoated silica gel plates (Merck, silica gel 60, 20 cm x 20 cm).  
Column chromatography was performed with silica gel 60 (Merck, particle size 0.040-
0.063 mm).  Proton NMR spectra were recorded at 298 K at 300 MHz on a Varian 
Unity Inova spectrometer; carbon NMR spectra were recorded at 75 MHz with the same 
instrument under the same conditions.  Instances where proton and carbon NMR spectra 
were recorded at 400 MHz, a Varian Oxford spectrometer or a Bruker Advance 
spectrometer were used, at an operating temperature of 298 K.  NMR spectra recorded 
at 600 MHz were performed using a Bruker Ultrashield spectrometer.  Chemical shifts 
are reported in parts per million (ppm) and refer to the respective deuterated solvents as 
reference, CDCl3 (1H 7.24 ppm, 13C 77.0 ppm), d6-DMSO (1H 2.49 ppm, 13C 39.5 ppm) 
and D2O (1H 4.79 ppm, 13C ppm referenced to CH3CN).  Infrared spectra were collected 
at 293 K by attenuated total reflection (ATR) using a Perkin Elmer Universal ATR 
Sampling Accessory attached to a Spectrum 100 FT-IR Spectrometer.  Wavenumbers 
are reported in units of cm-1.  All melting points are uncorrected.  Mass spectra were 
recorded using a Bruker micrOTOF-Q II Electron Spray Ionization (ESI) Mass 
Spectrometer (MS). 
 
Liquid Chromatography Mass Spectrometry (LC-MS) analysis was done using an 
Agilent 1100 Series LC with an Agilent 1100 Series LC/MS Trap by flow injection 
analysis.  Separation techniques were developed using an ACE 5 C18 A55055 column 
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(150 X 4.6 mm ACE-121-1546).  Separations for each compound were developed using 
gradient elution of water and acetonitrile (both containing 0.1% v/v formic acid).  
Separation techniques were then scaled up for use on semi-prep HPLC.  Purification by 
semi-prep HPLC was done using a Younglin ACME 9000 UV/VIS Detector and 
Gradient Pumps.  In all cases an ACE 5 C18 A54892 column (150 X 21.2 mm ACE-
121-1250) was used. 
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FeCl3.6H2O (0.48 g, 1.79 mmol) was dissolved in H2O (135 ml).  Sodium acetate (4.00 
g, 72.7 mmol) was added followed by glacial acetic acid (15 ml).  This solution was 
then heated and 2 % (m/v) 8-hydrozyquinoline in ethanol was added (45 ml).  The 
solution was refluxed for 30 min and the black precipitate collected by filtration (0.851 
g,  98%).  I.R. (υmax/cm-1) 3024, 1574, 1494, 1464, 1375, 1104, 737, 521. Elemental 
analysis for C27H18N3O3Fe: calculated %C 66.41, %H 3.72, %N 8.61; found: %C 65.09, 




CuCl2.2H2O (0.333 g, 1.99 mmol) was dissolved in H2O (135 ml).  Sodium acetate 
(4.00g, 72.7 mmol) was added, followed by glacial acetic acid (15 ml) and 2% (m/v) 8-
hydroxyquinoline in ethanol (34 ml).  The solution was refluxed till a green granular 
precipitate formed.  The green precipitate was filterd and washed with hot H2O (0.61 g, 
87%).  I.R. (υmax/cm-1) 3043, 1574, 1496, 1461, 1373, 1109, 740, 516. Elemental 
analysis for C18H12N2O2Cu: calculated %C 61.45, %H 3.44, %N 7.96; found: %C 
61.86, %H 3.51, %N 8.19. 
Fe(1,10-phen)3(ClO4)3 
 
1,10-phenanthroline hydrate was dissolved in H2O (50 ml) and heated.  
Fe(NH4)2SO4.6H2O (0.39 g, 1.32 mmol) was added.  Sodium prechlorate (0.30 g, 2.14 
mmol) was dissolved in H2O (10 ml) and added.  A dark red precipitate formed and was 
filtered and washed with hexane (0.70g, 0.74%).  I.R. (υmax/cm-1) 3436, 1518, 1427, 
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1086, 853, 722, 626. Elemental analysis for C24H16Cl3N4O12Fe: calculated %C 40.34, 




CuSO4.5H2O (0.660 g, 2.64 mmol) was dissolved in H2O (20 ml) and NaClO4 (0.76 g, 
6.21 mmol) 1,10-phenantholine hydrate was dissolved in ethanol (20 ml).  The two 
solutions were mixed and precipitate formed. The blue preciptitate that formed was 
collected (1.33 g, 81%).  I.R. (υmax/cm-1) 3071, 1527, 1440, 1082, 857, 731, 632.  
Elemental analysis for C24H16Cl2N4O8Cu: calculated  %C 46.28, %H 2.59, %N 9.00; 




Potassium chloroplatinate(II) (0.100 g, 0.241 mmol) was dissolved in H2O (5 ml).  Solid 
2,2':6',2''-terpyridine (0.056 g, 0.24 mmol) was then added to this solution followed by 
further H2O (2 ml).  The orange solution was then stirred under reflux overnight.  The 
reaction mixture was then cooled, any particulate matter filtered and the solvent 
removed under reduced pressure.  The resulting solid was then redissolved in a 
minimum of H2O and the product precipitated out by the addition of HCl (conc. approx. 
10 drops).  The bright orange product was filtered off and dried in a vacuum desiccator 
(0.042 g, 33%).  Mp >300 °C.  δH (400 MHz, DMSO-d6) 8.89 (dd, J=1.5 Hz, J=5.5 Hz, 
2H), 8.64 (m, 5H), 8.51 (td, J=8.0 Hz, J=1.5 Hz, 2H), 7.95 (m, 2H).  δC (100 MHz, 
DMSO-d6) 158.3, 154.4, 151.3, 142.7, 142.1, 129.2, 125.9, 124.5.  I.R. (υmax/cm-1) 
3297, 3031, 1604, 1476, 1451, 1401, 1314, 1249, 1091, 1030, 779, 721, 593, 546, 521, 







2,2':6',2''-Terpyridine (0.067 g, 0.29 mmol) was added to a solution of HAuCl4.H2O 
(0.100 g, 0.294 mmol) in H2O (7.5 ml).  This was followed by the addition of HCl (1 M, 
375 μl, 0.375 mmol).  The solution formed a yellow precipitate.  The pH was then 
adjusted to between 3 and 5 by adding NaOH (1 M, 240 μl, 0.240 mmol) giving an 
orange-red solution with a yellow precipitate.  The reaction mixture was refluxed 
overnight dissolving most of the precipitate.  After filtering (hot), the solvent was 
removed and the product recrystallized from H2O (0.090 g, 53%).  Mp 245-250 °C 
(decomp.).  δH (400 MHz, DMSO-d6) 8.77 (dd, J=1.5 Hz, J=5.0 Hz, 2H), 8.71 (d, J=8.0 
Hz, 2H), 8.49 (d, J=8.0 Hz, 2H), 8.15 (m, 3H), 7.60 (m, 2H).  δC (100 MHz, DMSO-d6) 
151.8, 151.5, 146.8, 141.5, 139.7, 126.0, 122.8, 122.7.  I.R. (υmax/cm-1) 3306, 3010, 
1602, 1476, 1449, 1401, 1322, 1249, 1089, 1028, 772, 761, 656, 542, 514, 441.  




2,2': 6',2''-Terpyridine (0.118 g, 0.506 mmol) was dissolved in methanol (20 ml) and 
added to a solution of CuCl2.2H2O (0.084 g, 0.493 mmol) in methanol (10 ml).  The 
terpyridine solution was added to the copper(II) chloride solution resulting in a colour 
change from light to dark green, followed by the formation of a green precipitate.  The 
solution was stirred for ten minutes and then left in a freezer for three days.  The 
product, a dark green powder, was filtered off and recrystallized from water to afford 
dark green crystals (0.139 g, 75%).  Mp >300 °C.  I.R. (υmax/cm-1) 3338, 3215, 1631, 
1595, 1562, 1489, 1428, 1407, 1302, 776, 737, 648, 625, 437, 408.  Calculated for 







2,2':6',2''-Terpyridine (0.100 g, 0.430 mmol) was dissolved in methanol (5 ml) and 
added to a solution of FeCl3.6H2O (0.111 g, 0.411 mmol) in methanol (15 ml).  The 
terpyridine solution was added to the iron(III) chloride solution, resulting in a colour 
change from yellow to red, followed by the formation of a yellow precipitate.  The 
solution was stirred for one hour at room temperature and filtered.  The product was 
recrystallized from water to afford amber crystals (0.122 g, 75%).  Mp >300 °C.  I.R. 
(υmax/cm-1) 3075, 1596, 1574, 1475, 1444, 1317, 1244, 1155, 1096, 1021, 780, 733, 
650, 512, 415.  Calculated for FeC15H11N3Cl2+ m/z = 358.9679.  Found: m/z = 358.9678 
[M]. 
 
[Pd(terpy)Cl]Cl.3H2O from PdCl2158 (63) 
 
Palladium(II) chloride was dissolved in H2O (10 ml) and HCl (32%, 3.00 ml, 31.5 
mmol) and heated to reflux.  The reaction mixture became clear red and was left for a 
further 45 minutes.  The warm solution was filtered and a solution of 2,2':6',2''-
terpyridine (0.120 g, 0.514 mmol) in methanol (10 ml) was added dropwise to the 
filtrate.  The newly formed peach-coloured precipitate was filtered off and the pH of the 
filtrate adjusted to between 4.5 and 5 using NaOH (2 M).  The solution was again 
filtered and the filtrate left until yellow-orange crystals formed (0.045 g, 19%).  Mp 
>300 °C.  δH (400 MHz, DMSO-d6) 8.72 (dd, J=1.5 Hz, J=5.5 Hz, 2H), 8.64 (m, 5H), 
8.46 (td, J=8.0 Hz, J=1.5 Hz, 2H), 7.88 (m, 2H).  δC (100 MHz, DMSO-d6) 158.0, 
154.6, 152.0, 142.8, 142.6, 128.9, 125.4, 124.5.  I.R. (υmax/cm-1) 3307, 3016, 1601, 
1448, 1400, 1320, 1247, 1088, 1027, 774, 719, 657, 566, 514, 440.  Calculated for 





[Pd(terpy)Cl]Cl.3H2O from PdCl2(DMSO)2158 (63) 
 
2,2':6',2''-Terpyridine (0.070 g, 0.30 mmol) was dissolved in methanol (10 ml) and 
added to a solution of PdCl2(DMSO)2 (0.100 g, 0.300 mmol) in methanol (20 ml).  A 
yellow precipitate was instantly formed but dissolved during refluxing (one hour).  The 
resulting clear yellow solution was filtered and concentrated under reduced pressure.  
The concentrated reaction mixture was left to crystallize, resulting in pale yellow 




Dimethyl sulfoxide (5.50 g, 70.4 mmol, 5 ml) was added to PdCl2 and the solution 
refluxed overnight.  Diethyl ether (20 ml) was then added to the solution to precipitate 
out a yellow-orange solid.  The mixture was stirred for ten minutes and filtered (0.233 g, 
78%).  Mp 203-205 °C (decomp.).  δH (400 MHz, DMSO-d6) 2.46 (s).  δC (100 MHz, 
DMSO-d6) 40.4.  Calculated for PdC4H13O2S2Cl2 m/z = 332.8769.  Found: m/z = 
332.9422 [M+H]. 
 
3-(2,4-Dihydroxy-3,3-dimethylbutanamido)propanoic acid (59) 
 
Pantothenic acid was prepared from the hemi-calcium salt, using Amberlite IR-120 H+ 
ion exchange resin.  The wet resin (20 ml) was loaded into a 50 ml burette.  Pantothenic 
acid hemi-calcium salt (0.238 g, 1 mmol) was dissolved in deionised water (10 ml) and 
loaded onto the column.  The column was eluted with deionised water at a flow rate of 
2-4 ml/min.  The acidic fractions were collected (approximately 40 ml) and dried by 
lyophilization to yield a clear to slightly yellow viscous oil (0.183 g, 84%).  Drying by 
any means involving heat resulted in discolouration and the generation of impurities 
(seen in NMR spectra).  δH (400 MHz, DMSO-d6) 3.87 (s, 1H), 3.39 (m, 3H), 3.28 (d, 
J=6.5 Hz, 2H) 0.81 (s, 3H), 0.77 (s, 3H).  δC (100 MHz, DMSO-d6) 180.4, 174.8, 75.8, 





Adenosine (2.00 g, 7.5 mmol) was added to CH3CN (25 ml) and the suspension cooled 
to -10 °C in an ice bath.  Freshly distilled thionyl chloride (2.68 g, 22.5 mmol, 1.64 ml) 
was then added, followed by dry pyridine (1.20 g, 14.9 mmol, 1.22 ml).  Upon the 
addition of pyridine the solution immediately turned yellow.  The reaction mixture was 
stirred for three hours at -5 °C and then allowed to reach room temperature and stirred 
overnight.  The solution was again cooled (0 °C) and H2O (60 ml) added.  A white 
precipitate formed on cooling but dissolved when the H2O was added.  This solution 
was then neutralized (pH 7) using solid NaHCO3, and extracted with ethyl acetate (3 x 
100 ml).  The organic phase was then washed with NaHCO3 (saturated, 150 ml), H2O 
(100 ml), dried over Na2SO4, filtered and evaporated under vacuum.  The white solid 
obtained was stirred in a mixture of CH3OH (50 ml), H2O (10 ml) and NH4OH (conc. 5 
ml) for 30 minutes.  The solvent was removed and the product recrystallized from H2O 
to give white needles (1.786 g, 72%).  Mp 188 °C (decomp.).  δH (400 MHz, DMSO-d6) 
8.34 (s, 1H), 8.15 (s, 1H), 7.31 (s, 2H), 5.93 (d, J=5.5 Hz, 1H), 5.61 (d, J=4.5 Hz, 1H), 
5.48 (d, J=4.5 Hz, 1H), 4.75 (d, J=5.5 Hz, 1H), 4.22 (d, J=4.0 Hz, 1H), 4.09 (d, J=4.0 
Hz, 1H), 3.93 (m, 1H), 3.83 (m, 1H).  δC (100 MHz, DMSO-d6) 156.1, 152.8, 149.5, 
139.8, 119.2, 87.5, 83.7, 72.7, 71.3, 44.9.  I.R. (υmax/cm-1) 3148, 1650, 1600, 1579, 
1483, 1422, 1389, 1337, 1298, 1208, 1131, 1097, 1053, 1038.  Calculated for 





Acetone (150 ml) was added to adenosine (0.34 g, 1.3 mmol).  para-Toluenesulphonic 
acid (PTSA, 2.00 g, 11 mmol) was added to the stirring mixture.  Upon the addition of 
PTSA the adenosine dissolved quickly, resulting in a clear colourless solution which 
was stirred at room temperature overnight.  The reaction mixture was then neutralized 
with NaHCO3 (1.60 g, 19.0 mmol) in water (50 ml).  The acetone was removed under 
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vacuum and the remaining water was extracted with chloroform (3 X 50 ml).  The 
organic layer was dried (MgSO4), filtered and the solvent removed, to afford a white 
solid (0.313 g, 80%).  Mp 210 °C.  δH (400 MHz, DMSO-d6) 8.33 (s, 1H), 8.14 (s, 1H), 
7.35 (s, 2H), 6.11 (d, J=3.0 Hz, 1H), 5.33 (dd, J=3.0 Hz, J=6.0 Hz, 1H), 5.24 (t, J=6.0 
Hz, 1H), 4.95 (dd, J=3.0 Hz, J=6.0 Hz, 1H), 4.20 (m, 1H), 3.54 (m, 2H), 1.52 (s, 3H), 
1.31 (s, 3H).  δC (100 MHz, DMSO-d6) 152.7, 148.8, 139.7, 119.1, 113.1, 89.6, 86.4, 
83.2, 81.4, 61.6, 27.1, 25.2.  I.R. (υmax/cm-1) 3272, 3127, 2986, 2938, 1679, 1610, 1571, 
1475, 1426, 1382, 1335, 1299, 1205, 1108, 1072, 850, 794, 721.  Calculated for 
C13H18N5O4 m/z = 308.1359.  Found: m/z = 308.1367 [M+H]. 
 
(3aR,4S,6R,6aS)-6-(6-Amino-9H-purin-9-yl)-2,2-
dimethyltetrahydrofuro[3,4-d][1,3]dioxole-4-carboxylic acid (65) 
 
Potassium hydroxide (0.179 g, 3.48 mmol) dissolved in water (54 ml) was added to the 
64 (0.326 g, 1.16 mmol).  Potassium permanganate (0.503 g, 3.48 mmol) was dissolved 
in water (27 ml) and added to the reaction mixture.  The solution was stirred overnight 
at room temperature and quenched with 7.5% H2O2 (15 ml).  The brown precipitate was 
filtered off and the filtrate concentrated to approximately 50 ml.  The product was 
precipitated out by acidification to ca. pH 4 using a 10% HCl solution.  The white solid 
was collected by filtration and dried in a vacuum desiccator (0.221 g, 64%).  Mp 258-
262 °C (decomp.).  δH (400 MHz, DMSO-d6) 8.23 (s, 1H), 8.07 (s, 1H), 7.26 (s, 2H), 
6.31 (s, 1H), 5.52 (dd, J=2.0 Hz, J=6.0 Hz, 1H), 5.45 (d, J=6.0 Hz, 1H), 4.67 (d, J=2.0 
Hz, 1H), 1.51 (s, 3H), 1.34 (s, 3H).  δC (100 MHz, DMSO-d6) 171.8, 157.1, 153.5, 
150.3, 141.5, 119.9, 113.8, 90.6, 86.5, 84.9, 84.5, 27.6, 26.1.  I.R. (υmax/cm-1) 3383, 
2979, 1702, 1614, 1499, 1378, 1278, 1204, 1104, 1054, 861, 768, 640, 519.  Calculated 





dihydroxytetrahydrofuran-2-carboxylic acid (66) 
 
65 (0.20 g, 0.623 mmol) was stirred in a TFA/H2O solution (1:4, 15 ml) at room 
temperature overnight.  The solvent was removed in vacuo to yield a white product 
(0.175 g, 100%).  Mp 190 °C (decomp.).  δH (400 MHz, DMSO-d6) 8.68 (s, 1H), 8.41 
(s, 1H), 6.07 (d, J=6.0 Hz, 1H), 4.52 (dd, J=5 Hz, J=6.0 Hz, 1H), 4.46 (d, J=2.0 Hz, 
1H), 4.32 (dd, J=3.0 Hz, J=4.0 Hz, 1H).  δC (100 MHz, DMSO-d6) 172.4, 152.9, 149.4, 
148.5, 141.4, 119.1, 87.8, 83.3, 74.7, 73.8.  I.R. (υmax/cm-1) 3512, 3215, 3147, 2941, 
2654, 2538, 1722, 1694, 1642, 1418, 1216, 1188, 1137, 1104, 1052, 855, 645, 592.  




1,10-Phenantholine hydrate (5.20 g, 26.26 mmol) and 98% H2SO4  (50.00 g, 500 mmol) 
were added together in a 250 ml round bottomed flask and heated to 120 °C.  To this 
solution 69% HNO3 (27 ml, 210 mmol) was added, resulting in the generation of brown 
fumes.  The temperature was then brought to approximately 170 °C at which point 
further HNO3 (69%, 50 ml, 390 mmol) was added dropwise maintaining the reaction 
temperature between 160 °C and 170 °C.  HNO3 was added until the generation of 
brown fumes (upon addition) ceased.  The reaction was then stirred for a further 30 
minutes without heating, and then poured directly onto crushed ice.  The orange 
solution was neutralized with 30% NaOH (blue to litmus paper) and then acidified again 
using 4 M nitric acid.  The neutralization results in the formation of a yellow precipitate, 
which was filtered, washed with water and put in a vacuum desiccator to dry (4.60 g, 
78%).  Mp 196-198 °C.  δH (400 MHz, CDCl3) 9.35 (dd, J =2.0 Hz, J=4.0 Hz, 1H), 9.29 
(dd, J=2.0 Hz, J=4.0 Hz, 1H), 9.02 (dd, J=2.0 Hz, J=8.0 Hz, 1H) 8.69 (s, 1H), 8.42 (dd, 
J=2.0 Hz, J=8.0Hz, 1H), 7.80 (m, 2H).  δC (100 MHz, CDCl3) 153.6, 151.5, 147.7, 
146.3, 144.3, 137.9, 132.5, 125.5, 125.4, 124.5, 121.1.  I.R. (υmax/cm-1) 3400, 3082, 
1516, 1505, 1420, 1355, 806, 733, 621.  Calculated for C12H8N3O2: m/z = 226.0617.  




A solution of 5-nitro-1,10-phenanthroline (0.600 g, 2.67 mmol) in ethanol (100 ml) was 
heated under nitrogen with stirring.  A small amount of Pd/C (1%, 0.300 g) was added 
to the reaction mixture.  A solution of hydrazine hydrate (1.03 g, 32.2 mmol, 1.00 ml) in 
ethanol (20 ml) was then added drop wise to the reaction mixture.  The reaction was 
then left to reflux overnight.  The solution was then filtered hot through sintered glass 
(porosity no. 4).  The filtrate was then concentrated in vacuo (temperature < 60 °C) to 
approximately 5 ml.  The yellow-green product was precipitated by adding H2O, 
vacuum filtered and dried in a vacuum desiccator (0.399 g, 76%). Mp 250 °C.  δH (400 
MHz, CDCl3) 9.18 (dd, J=2.0 Hz, J=4.0 Hz, 1H), 8.92 (dd, J=2.0Hz, J=5.0 Hz, 1H), 
8.26 (dd, J=2.0 Hz, J=8.0 Hz, 1H), 7.96 (dd, J=2.0 Hz, J=8.0 Hz, 1H), 7.63 (dd, J=4.0 
Hz, J=8.0 Hz, 1H), 7.48 (dd, J=4.0 Hz, J=8.0 Hz, 1H), 6.93 (s, 1H), 4.25 (b, 2H).  δC 
(100 MHz, CDCl3) 150.1, 147.1, 146.7, 142.4, 139.8, 133.5, 129.8, 129.4, 123.3, 122.3, 
122.2, 105.6.  .R. (υmax/cm-1) 3217, 1630, 1612, 1594, 1488, 1455, 1407, 1301, 859, 
802, 736, 625.  Calculated for C12H10N3: m/z = 196.0875.  Found: m/z = 
196.0922[M+H]. 
 
2-(tert-Butoxycarbonylamino)acetic acid178 (75) 
 
Di-tert-butyl dicarbonate (9.80 g, 44 mmol) was dissolved in diethyl ether (100 ml) and 
added to a solution of glycine (3.00 g, 40 mmol) dissolved in NaOH (1.6 M, 100 ml).  
The two solutions were then stirred vigorously overnight at room temperature.  
Following this the organic layer was separated from the aqueous layer.  The latter was 
kept and acidified to approximately pH 2 using HCl (10%, approx. 150 ml).  This 
solution was then extracted with ethyl acetate (3 x 150 ml), dried over Na2SO4 and the 
solvent removed under vacuum to afford a white solid (5.05 g, 72%).  Mp 86-87 °C.  
Peaks attributed to the E or Z conformation are indicated by E or Z in brackets after the 
chemical shift.  δH (400 MHz, CDCl3) 6.70 (Z, 0.33H) 5.06 (E, 0.67H), 3.93 (E and Z, 
m, 2H), 1.43 (s, 9H).  δC (100 MHz, CDCl3) 174.6 (E), 173.8 (Z), 157.1 (Z), 155.9 (E), 
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81.6 (Z), 80.4 (E), 43.4 (Z), 42.2 (E), 28.3 (E and Z).  I.R. (υmax/cm-1) 3407, 3343, 2978, 
2939, 1738, 1666, 1529, 1408, 1367, 1280, 1195, 1155, 1055, 957, 856, 579, 565.  
Calculated for C7H14NO4 m/z = 176.0923.  Found: m/z = 176.0933 [M+H]. 
 
tert-Butyl 2-(8-hydroxyquinolin-5-ylamino)-2-oxoethylcarbamate (76) 
 
A solution of dicyclohexylcarbodiimide (1.65 g, 8 mmol) in dry CH3CN (20 ml) and a 
solution of 2-(tert-butoxycarbonylamino)acetic acid (2.80 g, 16.0 mmol) in CH3CN (30 
ml) were added together, resulting in the immediate formation of a white precipitate.  
This solution was then left to stir for one hour, after which the white solid was filtered 
(sintered glass porosity no. 4) and the filtrate added to a solution of 5-amino-8-
hydroxyquinoline dihydrochloride (0.317 g, 1.29 mmol) in dry CH3CN (50 ml) with dry 
pyridine (0.572 g, 5.76 mmol, 0.72 ml).  The resulting red solution was left to stir at 
room temperature, under N2, for 48 hours.  The solvent was removed and the resulting 
solid dissolved in dichloromethane and washed with NaHCO3 (5%, 100 ml).  The 
organic layer was dried using Na2SO4 and preadsorbed onto silica.  The product was 
purified by column chromatography using gradient elution, from 100% hexane to 50% 
ethyl acetate/hexane.  The product was isolated as a pale yellow solid (0.152 g, 37%).  
Mp 134-135 °C.  δH (400 MHz, DMSO-d6) 9.76 (s, 1H), 8.85 (dd, J=1.5 Hz, J=8.0 Hz, 
1H), 8.31 (dd, J=6.5 Hz, J=8.0 Hz, 1H), 7.56 (m, 1H), 7.39 (d, J=8.0 Hz, 1H), 7.12 (m, 
1H), 7.05 (d, J=8.0 Hz, 1H), 3.81, (d, J=6.5 Hz, 2H), 1.40 (s, 9H).  δC (100 MHz, 
DMSO-d6) 169.4, 156.0, 151.8, 148.1, 138.3, 132.2, 124.7, 124.3, 124.1, 121.4, 110.4, 
78.1, 43.7, 28.2.  I.R. (υmax/cm-1) 3318, 2977, 1713, 1691, 1652, 1505, 1365, 1272, 
1223, 1167, 1053, 942, 780, 563, 495.  Calculated for C16H20N3O4 m/z = 318.1454.  




A mixture of freshly distilled TFA (5 ml, 29.6 mmol) and dry CH2Cl2 (5 ml) was added 
to tert-butyl 2-(8-hydroxyquinolin-5-ylamino)-2-oxoethylcarbamate (0.350 g, 1.10 
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mmol) and the solution stirred for two hours.  The solvent was then removed in vacuo 
affording a green-yellow product (0.234 g, 98%)  Mp 210-212 °C (decomp.).  δH (400 
MHz, DMSO-d6) 10.35 (s, 1H), 8.93 (d, J=4 Hz, 1H), 8.52 (d, J=8.0 Hz, 1H), 8.17 (b, 
1H), 7.69 (dd, J=2 Hz, J=4 Hz, 1H), 7.52 (d, J=8.0 Hz, 1H), 7.16 (d, J=8.0 Hz, 1H), 
3.92 (m, 2H).  δC (100 MHz, DMSO-d6) 166.1, 158.5, 151.0, 147.7, 136.6, 134.0, 124.7, 
123.4, 121.8, 111.6, 40.8.  I.R. (υmax/cm-1) 3277, 3061, 1721, 1687, 1662, 1601, 1562, 
1315, 1185, 1123, 1084, 842, 828, 797, 726, 720.  Calculated for C11H12N3O2 m/z = 
218.0930.  Found: m/z = 218.0954 [M+H]. 
 
8-Hydroxyquinoline-pantothenic acid derivative (78) 
 
Dry pantothenic acid (0.0954 g, 0.436 mmol) was dissolved in dry DMF (5 ml).  77 
(0.0945 g, 0.436 mmol) was added to the reaction mixture, which turned green-brown, 
followed by DPPA (0.132 g, 0.479 mmol).  The reaction was then cooled to 0 °C and 
TEA (0.067 ml, 0.479 mmol) was added.  The reaction was stirred at 0 °C for 2 hours 
and then allowed to warm to room temperature and stirred overnight.  The reaction was 
monitored using LC-MS and the product purified using semi-prep HPLC to afford a 
viscous yellow oil (0.067 g, 36 %).  Gradient elution (water and acetonitrile both 
containing 0.1% v/v formic acid) for semi-prep HPLC was as follows:  using a flow rate 
of 17 ml.min-1 the gradient was held at 90% water to for two minutes and then changed 
to 87% water over 6 minutes.  Product retention time 3.1 min.  δH (400 MHz, DMSO-
d6) 9.87 (s, 1H), 8.91 (d, J=2.0 Hz, 1H), 8.44 (d, J=8.0 Hz, 1H), 8.35 (t, J=5.0 Hz, 1H), 
8.13 (s, 1H), 7.76 (t, J=5.0 Hz, 1H), 7.68 (dd, J=4.0 Hz, J=8.0 Hz, 1H), 7.44 (d, J=8.0 
Hz, 1H), 7.13 (d, J=8.0 Hz, 1H), 3.97 (d, J=6.0 Hz, 2H), 3.69 (s, 1H), 3.16- 3.28 (m, 
4H, suppressed), 2.41 (m, 2H), 0.79 (s, 3H), 0.78 (s 3H).  δC (100 MHz, DMSO-d6) 
172.9, 171.4, 169.1, 163.1, 150.7, 147.5, 136.7, 134.2, 125.0, 124.9, 124.3, 121.6, 
111.4, 75.1, 68.0, 42.6, 35.1, 34.8, 21.0, 20.4.  I.R. (υmax/cm-1) 3278, 3072, 2964, 1646, 
1598, 1524, 1475, 1277, 1197, 1179, 1130, 1078, 1036, 832, 798, 719, 598.  Calculated 
for C20H27N4O6 m/z = 419.1931.  Found: m/z = 419.1944 [M+H]. 
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8-Hydroxyquinoline-adenosine derivative (79) 
 
77 (0.039 g, 0.178 mmol) and 66 (0.050 g, 0.178 mmol) were dissolved in dry DMF (5 
ml).  HBTU (0.0674 g, 0.178 mmol) and TEA (0.148 g, 1.068 mmol) were added to the 
reaction mixture.  The resulting solution was stirred at room temperature overnight and 
monitored by LC-MS.  The product was purified using semi-prep HPLC to afford a 
yellow solid (0.027 g, 32 %).  Gradient elution (water and acetonitrile both containing 
0.1% v/v formic acid) conditions for semi-prep HPLC were as follows:  using a flow 
rate of 17 ml.min-1 the gradient was changed from 96% water to 95% water over 20 
minutes.  Product retention time 4.5 min.  Mp 226-228 °C (decomp.).  δH (400 MHz, 
DMSO-d6) 9.94 (s, 1H), 9.27 (s, 1H), 8.89 (d, J=3.0 Hz, 1H), 8.51 (s, 1H), 8.41 (d, 
J=3.0 Hz, 1H), 8.26, (s, 1H), 7.63, (dd, J=4 Hz, J=8.0 Hz, 1H), 7.45 (d, J=8.0 Hz, 1H), 
7.09 (d, J=8.0 Hz, 1H), 6.03 (d, J=7.0 Hz, 1H), 4.67 (dd, J=4.0 Hz, J=7.0 Hz, 1H), 4.46 
(s, 1H), 4.17-4.24 (m, 3H).  δC (100 MHz, DMSO-d6) 170.8, 169.0, 156.8, 151.9, 151.5, 
149.4, 148.3, 141.3, 138., 125.1, 124.9, 124.6, 122.0, 119.7, 111.3, 87.9, 85.1, 73.8, 
72.8, 42.8.  I.R. (υmax/cm-1) 3327, 3192, 3070, 2926, 1643, 1597, 1503, 1475, 1374, 






A solution of dicyclohexylcarbodiimide (1.65 g, 8 mmol) in dry CH3CN (20 ml) and a 
solution of 2-(tert-butoxycarbonylamino)acetic acid (2.80 g, 16.0 mmol) in dry CH3CN 
(30 ml) were added together, resulting in the immediate formation of a white 
precipitate.  This solution was then left to stir for one hour, after which the white solid 
was filtered off (sintered glass porosity no. 4) and the filtrate added to a solution of 5-
amino-1,10-phenanthroline (0.300 g, 1.54 mmol) in dry CH3CN (50 ml).  The resulting 
yellow solution was left to stir at room temperature, under N2, overnight.  The reaction 
was monitored using UV TLC plates with a mobile phase of 20% methanol in 
dichloromethane (product Rf = 0.50).  Normal TLC plates showed no distinction 
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between product and starting material.  The solvent was removed and the resulting solid 
dissolved in dichloromethane and then washed with NaHCO3 (5%, 100 ml).  The 
organic layer was dried using Na2SO4 and preadsorbed onto silica.  The product was 
purified by column chromatography using gradient elution, from 100% CH2Cl2 to 6% 
CH3OH/CH2Cl2.  The product was isolated as a pale yellow solid (0.295 g, 55%).  Mp 
140-150 °C (decomp.).  δH (400 MHz, DMSO-d6) 10.15 (s, 1H), 9.12 (d, J=2.0 Hz, 1H), 
9.03 (d, J=2.0 Hz, 1H), 8.61 (d, J=8.0 Hz, 1H), 8.45 (d, J=8.0 Hz, 1H), 8.13 (s, 1H), 
7.75 (m, 2H), 7.20 (s, 1H), 3.93 (d, J=6.0 Hz, 2H), 1.48 (s, 9H).  δC (100 MHz, DMSO-
d6) 169.6, 156.1, 149.9, 149.4, 145.8, 143.9, 135.9, 131.8, 131.6, 128.1, 124.8, 123.6, 
122.8, 120.3, 78.2, 43.9, 28.2.  I.R. (υmax/cm-1) 3192, 2979, 1710, 1685, 1644, 1620, 
1524, 1481, 1420, 1366, 1282, 1167, 740.  Calculated for C19H21N4O3 m/z = 353.1614.  




A mixture of freshly distilled trifluoroacetic acid (TFA, 5 ml, 29.6 mmol) and dry 
CH2Cl2 (5 ml) was added to tert-butyl 2-(1,10-phenanthrolin-5-ylamino)-2-
oxoethylcarbamate (0.100 g, 0.284 mmol) and the solution stirred for two hours.  The 
solvent was then removed in vacuo affording an orange product (0.072 g, 100%)  Mp 
122 °C.  δH (400 MHz, DMSO-d6) 10.91 (s, 1H), 9.30 (d, J=4.0 Hz, 1H), 9.19 (d, J=4.5 
Hz, 1H), 8.98 (t, J=8.0 Hz, 2H), 8.44 (s, 1H), 8.29 (s, 1H), 8.11 (m, 1H), 4.08 (d, J=4.0 
Hz, 2H) .  δC (100 MHz, DMSO-d6) 166.5, 158.1, 149.8, 147.5, 142.1, 139.9, 133.7, 
131.9, 128.7, 124.9, 124.8, 124.3, 119.4, 41.2.  I.R. (υmax/cm-1) 3284, 3243, 2920, 1670, 
1593, 1540, 1502, 1466, 1425, 1191, 1174, 1131, 866, 835, 810, 797, 722, 621, 474.  
Calculated for C14H13N4O m/z = 253.1089.  Found: m/z = 253.1108 [M+H]. 
 
1,10-Phenanthroline-pantothenic acid derivative (82) 
 
Dry pantothenic acid (0.107 g, 0.488 mmol) was dissolved in dry DMF (5 ml).  81 
(0.123 g, 0.489 mmol) was added to the reaction mixture, which turned bright orange, 
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followed by DPPA (0.148 g, 0.534 mmol).  The reaction was then cooled to 0 °C and 
triethylamine (TEA, 0.074 ml, 0.534 mmol) was added.  The reaction was stirred at 0 
°C for two hours and then allowed to warm to room temperature and stirred overnight.  
The reaction was monitored using LC-MS and the product purified using semi-prep 
HPLC to afford a viscous orange oil (0.042 g, 19 %).  Gradient elution (water and 
acetonitrile both containing 0.1% v/v formic acid) for semi-prep HPLC was as follows:  
using a flow rate of 17 ml.min-1 the gradient was changed from 90% water to 86% water 
over 8 minutes.  Product retention time 7 minutes.  δH (400 MHz, DMSO-d6) 10.20 (s, 
1H), 9.13 (d, J=3.0 Hz, 1H), 9.05 (d, J=3.0 Hz, 1H), 8.60 (d, J=8 Hz, 1H), 8.46 (d, J=8 
Hz, 1H), 8.41 (t, J=5 Hz, 1H), 7.83 (dd, J=5.0 Hz, J=8.0 Hz, 1H) 7.76 (m, 2H), 4.08 (d, 
J=5 Hz, 2H), 3.71 (s, 1H), 3.18-3.41 (m, 4H, suppressed), 2.42 (m, 2H), 0.81 (s, 3H), 
0.79 (s, 3H).  δC (100 MHz, DMSO-d6) 173.4, 171.9, 169.7, 163.6, 150.4, 149.9, 146.3, 
144.4, 136.3, 132.3, 132.1, 128.5, 125.4, 124.1, 123.3, 121.1, 75.6, 74.7, 68.5, 43.2, 
38.1, 35.6, 35.3, 21.3, 20.8.  I.R. (υmax/cm-1) 3632, 3277, 1776, 1653, 1599, 1543, 1466, 
1119, 1024, 991, 937, 765, 724, 557.  Calculated for C23H28N5O5 m/z = 454.2090.  
Found: m/z = 454.2113 [M+H]. 
 
1,10-Phenanthroline-adenosine derivative (83) 
 
81 (0.045 g, 0.178 mmol) and 66 (0.050 g, 0.178 mmol) were dissolved in dry DMF (5 
ml).  HBTU (0.0674 g, 0.178 mmol) and TEA (0.148 g, 1.068 mmol) were added to the 
reaction mixture.  The resulting solution was stirred at room temperature overnight and 
monitored by LC-MS.  The product was purified using semi-prep HPLC to afford an 
orange solid (0.018 g, 20 %).  Gradient elution (water and acetonitrile both containing 
0.1% v/v formic acid) for semi-prep HPLC was as follows:  using a flow rate of 17 
ml.min-1 the gradient was changed from 95% water to 91% water over eight minutes.  
Product retention time 8.7 minutes.  Mp 250-254 °C (decomp.).  δH (400 MHz, DMSO-
d6) 10.30 (s, 1H), 9.52 (t, J=5.0 Hz, 1H), 9.13 (d, J=3.5 Hz, 1H), 9.04 (d, J=3.5 Hz, 1H), 
8.66 (d, J=8.0 Hz, 1H), 8.46 (d, J=8.0 Hz, 1H), 8.44 (s, 1H) 8.16 (s, 1H), 8.13 (s, 1H) 
7.83 (dd, J=4.0 Hz, J=4.0 Hz, 1H), 7.74 (dd, J=4.0 Hz, J=4.0 Hz, 1H), 7.42 (s, 2H), 
6.03 (d, J=8.0 Hz, 1H), 4.71 (dd, J=5.0 Hz, J=3.0 Hz, 1H), 4.46 (s, 1H), 4.28 (m, 3H).  
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δC (100 MHz, DMSO-d6) 170.5, 168.8, 156.2, 152.5, 149.9, 149.2, 148.9, 145.5, 143.5, 
140.5, 136.1, 131.9, 131.6, 128.1, 124.7, 123.7, 122.9, 120.1, 119.5, 57.5, 84.7, 73.3, 
72.0, 42.5.  I.R. (υmax/cm-1) 3435, 3171, 3067, 2920, 1643, 1594, 1540, 1421, 1329, 
1206, 1129, 1046, 798, 739, 522.  Calculated for C24H22N9O5 m/z = 516.1744.  Found: 




4-Chloro-2;2':6';2''-terpyridine (0.180 g, 0.672 mmol) was refluxed in ethylenediamine 
(11.12 g, 189 mmol, 10 ml,).  The solution was initially yellow and became dark brown 
overnight.  The solution was then concentrated under vacuum, and the product 
precipitated out by adding H2O.  This golden precipitate was filtered, washed with water 
and dried in a vacuum desiccator (0.133 g, 68%).  Mp 156-159 °C.  δH (400 MHz, 
CDCl3) 8.65 (ddd, J=1.5 Hz, J=2.0 Hz, J=5.5 Hz, 2H), 8.59 (dt, (J=8.0 Hz, J=1.0 Hz, 
2H), 7.80 (ddd, J=1.5 Hz, J=5.5 Hz, J=8.0 Hz, 2H), 7.68 (s, 2H), 7.28 (ddd, J=1.0 Hz, 
J=5.5 Hz, J=8.0 Hz, 2H), 4.86 (t, J=5.0 Hz, 1H), 3.41 (m, 2H), 3.00 (m, 2H).  δC (100 
MHz, CDCl3) 156.8, 155.9, 155.5, 148.8, 136.7, 123.5, 121.3, 104.8, 45.3, 41.0.  I.R. 
(υmax/cm-1) 3289, 2878, 1606, 1582, 1563, 1462, 1331, 1225, 1040, 984, 789, 744, 731, 
629, 404.  Calculated for C17H18N5 m/z = 292.1562.  Found: m/z = 292.1574 [M+H]. 
 
2,2':6',2'' Terpyridine-pantothenic acid derivative (90) 
 
Dry pantothenic acid (0.183 g, 0.836 mmol) was dissolved in dry DMF (5 ml).  89 
(0.243 g, 0.836 mmol) was added to the reaction mixture followed by DPPA (0.200 g, 
0.920 mmol).  The reaction was then cooled to 0 °C and TEA (0.130 ml, 0.920 mmol) 
was added.  The reaction was stirred at 0 °C for two hours and then allowed to warm to 
room temperature and stirred overnight.  The reaction was monitored using LC-MS and 
the product purified using semi-prep HPLC to afford a viscous purple oil (0.216 g, 
55.3%).  Gradient elution (water and acetonitrile both containing 0.1% v/v formic acid) 
conditions for semi-prep HPLC were as follows:  using a flow rate of 17 ml.min-1 the 
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gradient was changed from 82% water to 81% water over eight minutes, then to 65% 
water over two minutes where it was held constant for four minutes.  Product retention 
time 10 minutes.  δH (400 MHz, D2O) 8.60 (m, 2H), 8.38 (s, 1H), 7.99 (m, 4H), 7.59 (t, 
J=5.0 Hz, 2H), 7.33 (t, J=6.0 Hz, 2H), 7.15 (m, 2H), 3.89 (s, 1H), 3.27-3.40 (m, 8H), 
2.44 (t, J=6.0 Hz, 2H) 0.82 (s, 3H), 0.78 (s, 3H).  δC (100 MHz, D2O-d6) 175.0, 174.4, 
168.9, 149.5, 138.8, 129.7, 127.0, 124.4, 121.7, 120.1, 120.0, 75.6, 68.2, 41.8, 38.5, 
37.9, 35.3, 20.4, 19.0.  I.R. (υmax/cm-1) 3242, 3061, 2936, 2872, 1637, 1584, 14878, 
1234, 1206, 1089, 1072, 909, 893, 765, 692, 532.  Calculated for C26H33N6O4 m/z = 
493.2563.  Found: m/z = 493.2570 [M+H]. 
 
2,2';6',2'' Terpyridine-adenosine derivative (91) 
 
89 (0.051 g, 0.178 mmol) and 66 (0.050 g, 0.178 mmol) were dissolved in dry DMF (5 
ml).  HBTU (0.0674 g, 0.178 mmol) and TEA (0.148 g, 1.068 mmol) were added to the 
reaction mixture.  The resulting solution was stirred at room temperature overnight and 
monitored by LC-MS.  The product was purified using semi-prep HPLC to afford a 
purple solid (0.023 g, 28%).  Gradient elution (water and acetonitrile both containing 
0.1% v/v formic acid) conditions for semi-prep HPLC were as follows:  using a flow 
rate of 17 ml.min-1 the gradient was changed from 80% water to 60% water over ten 
minutes.  Product retention time 10 minutes.  Mp 175 °C.  δH (400 MHz, DMSO-d6) 
9.29 (s, 1H), 8.73 (m, 2H), 8.49 (m, 2H), 8.37 (s, 1H), 8.23 (s, 1H), 8.00 (m, 2H), 7.68 
(s, 2H), 7.51 (m, 2H), 7.41 (s, 2H), 5.95 (d, J=8.0 Hz, 1H), 4.63 (d, J=4.0 Hz, 1H), 4.35 
(s, 1H), 4.20 (s, 1H), 3.50 (t, J=6.0 Hz, 2H suppressed), 2.90 (t, J=6.0 Hz, 2H 
suppressed).  δC (100 MHz, DMSO-d6) 170.6, 163.6, 156.7, 153.0, 149.7, 149.6, 149.2, 
141.2, 138.0, 124.7, 123.8, 121.4, 120.1, 88.3, 85.2, 73.6, 72.4, 42.2, 38.3.  I.R. 
(υmax/cm-1) 3183, 1647, 1585, 1567, 1472, 1337, 1119, 1052, 790, 744, 693.  Calculated 
for C27H27N10O4 m/z = 555.2217.  Found: m/z = 555.2204 [M+H]. 
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7.3 Inhibition of β-Haematin Formation Assays 
A simple method for screening a compounds ability to inhibit the formation of β-
haematin was developed by Egan, Ross and Adams.28  Their method was adapted for 
this study.  A sample of haemin (15 mg, 0.023 mmol) was placed in a test tube with 
NaOH (0.1 M, 3 ml).  This mixture was heated to 70 °C.  To this solution was added 
first an acetate buffer solution (12.9 M, pH 5, 1.75 ml) followed by HCl (1 M, 0.30 ml) 
both pre-incubated at 70 °C.  After stirring for two hours in a temperature controlled 
bath, the test tube was placed on ice for five minutes.  In the study by Egan et al28 β-
haematin was found to form within 30 minutes at 60 °C, however here it was found that 
the formation of β-haematin was only complete after two hours at 70 °C.  Once cooled 
the contents of the test tubes were transferred to vials, and centrifuged at 6000 rpm for 
five minutes.  The supernatant was decanted, and the remaining solid was shaken with 
deionised water (8 ml) and centrifuged again at 6000 rpm for five minutes.  The solid 
was washed in this way three times following which, while still wet, it was analysed 
using an ATR infrared spectrophotometer (no difference was found whether the sample 
was left to dry on the spectrophotometer, usually within a few minutes, or if it was dried 
in a desiccator prior to infrared analysis.)  This control experiment was used to confirm 
β-haematin formation under the reaction conditions.  The effect of each compound was 
determined by adding three equivalents to the test tube prior to the addition of the 
acetate buffer solution.  In each run a negative inhibition control (haemin alone) and a 
positive inhibition control (a reaction mixture containing three equivalents of 
chloroquine phosphate) was used.  The formation of β-haematin may be determined by 
the appearance of two peaks on the infrared spectrum of solid residue, one at 1660 cm-1 
and one at 1207 cm-1.28 
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7.4 Antimalarial Activity Screening Method∗ 
Parasite culture  
 
The 3D7 and D10 strains of P. falciparum was cultured at 37 °C in RPMI-1640 medium 
supplemented with 50 mM glucose, 0.65 mM hypoxanthine, 25 mM Hepes, 0.2% (w/v) 
NaHCO3, 0.048 mg/ml gentamicin, 0.5% (w/v) Albumax II, and 2-4% (v/v) human O+ 
erythrocytes, under an atmosphere of 3% CO2, 4% O2, balance N2. 
 
Parasite viability dose-response assays 
 
Culture-derived parasitised erythrocytes were mixed with fresh culture medium and 
erythrocytes to yield a 2% parasitemia, 2% haematocrit suspension and distributed in 
microtitre plates at 100 µl/well. Serial dilutions of test drug in culture medium were 
prepared in quadruplicate wells in a separate plate and transferred to the parasite plate to 
yield a final volume of 200 µl/well. The plates were incubated at 37oC for 48 hours and 
parasite viability in each well measured by the colorimetric determination of parasite 
lactate dehydrogenase activity.179  The IC50-values were obtained using a non-linear 
dose-response curve fitting analysis via Graph Pad Prism v.4.0 software. 
                                                 
∗ All antimalarial testing was performed either by Dr H Hoppe or Prof. P. Smith at the University of Cape 
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Appendix 2  




Spectrum 94 IR spectrum of β-haematin positive control. 
 
 








Spectrum 96 IR spectrum of K2PtCl4 β-haematin assay. 
 
 
Spectrum 97 IR spectrum of HAuCl4 β-haematin assay. 
 234
 
Spectrum 98 IR spectrum of CuCl2 β-haematin assay. 
 
 




Spectrum 100 IR spectrum of PdCl2 β-haematin assay. 
 
 








Spectrum 102 IR spectrum of 33 β-haematin assay. 
 
 














Spectrum 104 IR spectrum of 62 β-haematin assay. 
 
 














Spectrum 106 IR spectrum of 59 β-haematin assay. 
 
 


















Spectrum 108 IR spectrum of 1 β-haematin assay. 
 
 












Spectrum 110 IR spectrum of 78 β-haematin assay. 
 
 





























Spectrum 112 IR spectrum of 16 β-haematin assay. 
 
 










Spectrum 114 IR spectrum of 82 β-haematin assay. 
 
 


























Spectrum 116 IR spectrum of 29 β-haematin assay. 
 
 












Spectrum 118 IR spectrum of 90 β-haematin assay. 
 
 
Spectrum 119 IR spectrum of 91 β-haematin assay. 
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